| Excerpt | Reference |
|---|
| "The condition of preeclampsia is not well defined." | ( Bonnar, J; Denson, KW; Redman, CW, 1976) |
| "Preeclampsia is associated with an imbalance of increased thromboxane and decreased prostacyclin and an abnormal increase of lipid peroxides." | ( Kay, HH; McCoy, MC; Walsh, SW; Wang, Y, 1992) |
| "Preeclampsia is characterized by a generalized disturbance in endothelial physiology, and not merely by an isolated defect in vascular prostacyclin synthesis." | ( Dekker, GA; van Geijn, HP, 1992) |
| "Preeclampsia is diagnosed when the systolic blood pressure (BP) increases by 30 mm Hg or the diastolic BP increases by 15 mm Hg after the 20th week of gestation and the BP rise is accompanied by edema, proteinuria, or both." | ( McCombs, J, 1992) |
| "Preeclampsia is associated with an imbalance between thromboxane and prostacyclin." | ( Guo, JD; Walsh, SW; Wang, YP; Zhang, JY, 1991) |
| "Preeclampsia is a syndrome of unknown etiology characterized by the sequential development of facial and hand edema, hypertension, and proteinuria after the 20th week of gestation." | ( Zuspan, FP, 1991) |
| "Preeclampsia is a disease unique to pregnancy." | ( Repke, JT, 1991) |
| "Preeclampsia is characterized by enhanced pressor responsiveness to angiotensin II." | ( Maruo, T; Mochizuki, M; Morikawa, H; Yamasaki, M, 1991) |
| "The ANP in preeclampsia is not related directly to hypertension, but it may play a substantial role in the regulation or normalization of blood volume and vascular reactivity." | ( Furuhashi, N; Kimura, C; Kimura, H; Nagae, H; Tsujiei, M; Yajima, A, 1991) |
| "Preeclampsia is characterized by increased vascular sensitivity to Angiotensin II, endothelial damage, and arteriolar spasm." | ( Katz, VL; Krege, JH, 1990) |
| "Although preeclampsia is an important and relatively common medical problem, its pathophysiology remains unresolved and the search for a biochemical marker that precedes the hemodynamic abnormalities of preeclampsia continues." | ( Berry, S; Kowalczyk, C; Norman, G; Sokol, RJ; Sowers, JR; Standley, PR; Walsh, MF; Zemel, MB; Zemel, PC, 1990) |
| "Preeclampsia is characterized by a generalized vasoconstriction and increased vascular sensitivity to angiotensin II." | ( Distler, A; Haller, H; Hauck, U; Oeney, T; Philipp, T, 1989) |
| "Preeclampsia is characterized by imbalances in the production rates of several arachidonic acid metabolites." | ( Parisi, VM; Walsh, SW, 1986) |
| "Preeclampsia is a disorder of pregnancy characterized clinically by hypertension, proteinuria, and edema and characterized pathologically in its late stages by widespread microvascular thrombi." | ( Jacob, HS; Moldow, CF; Ogburn, PL; Watson, KV, 1986) |
| "We conclude that preeclampsia is associated with hypocalciuria due to increased tubular reabsorption of calcium." | ( Ales, KL; Druzin, ML; Gertner, JM; Laragh, JH; Resnick, LM; Taufield, PA, 1987) |
| "Preeclampsia is characterized by increased vasoconstriction frequently associated with increased platelet aggregation, reduced uteroplacental blood flow, and premature delivery." | ( Walsh, SW, 1985) |
| "When preeclampsia is accompanied by proteinuria there is a marked fall in albumin and an increase in alpha(2)-macroglobulin." | ( Goudie, RB; Horne, CH; Howie, PW, 1970) |
| "Preeclampsia is associated with increased peripheral, uterine, and umbilical artery resistance." | ( Akovic, K; Anthony, J; Belfort, M; Kirshon, B; Moise, K; Saade, G, 1994) |
| "Preeclampsia is associated with a greater increase in plasma ANP levels in response to volume expansion compared with normotensive pregnancy." | ( Direm, B; Gökmen, O; Ozcan, T; Sahin, N; Senöz, S, 1995) |
| "Preeclampsia is a pregnancy-specific disorder believed to result from widespread endothelial dysfunction." | ( Ahokas, RA; Friedman, SA; Lubarsky, SL; Nova, A; Sibai, BM, 1995) |
| "Preeclampsia is not associated with an increase in the responses of fetal placental arteries to vasoconstrictors or a decrease in their response to vasodilators." | ( Chemtob, S; Inayatulla, A; Nuwayhid, B; Varma, DR, 1993) |
| "Toxemia of pregnancy is considered to represent a disorder of activated blood coagulation." | ( Ishii, Y; Kanai, H; Maezawa, A; Naruse, T; Tsuchida, A; Yano, S, 1993) |
| "Preeclampsia is accompanied by amplification of the sodium retention that is a feature of normal pregnancy." | ( Brown, MA; Edwards, CR; Honour, JW; Walker, BR; Whitworth, JA; Williamson, PM, 1995) |
| "Preeclampsia is characterized by a functional imbalance between vascular prostacyclin and thromboxane A2 production." | ( Egarter, C; Husslein, P; Karas, H, 1993) |
| "Preeclampsia is characterized by a generalized disturbance in endothelial physiology, and not merely by an isolated defect in vascular prostacyclin synthesis." | ( Dekker, GA, 1994) |
| "Preeclampsia is a disease of late pregnancy characterized by hypertension, edema, and proteinuria, in which vasoconstriction, platelet aggregation, and reduced uteroplacental blood flow contribute to preterm delivery, perinatal morbidity, and mortality." | ( Lei, ZM; Li, X; Rao, CV; Spinnato, JA; Tanabe, T; Ullrich, V; Woodworth, SH; Yokoyama, C; Yussman, MA, 1994) |
| "Preeclampsia is an important cause of fetal and maternal morbidity and mortality." | ( Boer, GJ; Boer, K; Konijnenberg, A; Schaap, MC; Sturk, A; Swaab, DF; van Boxtel, CE; van der Post, JA, 1993) |
| "Preeclampsia is associated with hypertension, fetal growth retardation, and proteinuria." | ( Garfield, RE; Yallampalli, C, 1993) |
| "Severe preeclampsia is associated with an abnormality of tissue oxygen extraction, as evidenced by a low and unresponsive oxygen extraction ratio." | ( Anthony, J; Belfort, MA; Clark, S; Johanson, R; Moise, KJ; Saade, GR; Wasserstrum, N, 1993) |
| "Preeclampsia is frequently treated with the intravenous infusion of magnesium sulphate, which is well known to control seizures in the eclamptic patient." | ( Belfort, MA, 1993) |
| "Preeclampsia is characterized by the presence of a neutrophil activator that enhances superoxide production." | ( Ishida, K; Koyanagi, T; Maeda, H; Nagata, H; Nakano, H; Tsukimori, K, 1993) |
| "Preeclampsia is characterized by a functional imbalance between vascular prostacyclin and thromboxane A2 production." | ( Dekker, GA; Sibai, BM, 1993) |
| "Severe preeclampsia is the most distinctive and life-threatening form; a multi-system disorder more common in first pregnancies, it is characterized by high blood pressure and proteinuria." | ( Farrington, PF; Hata, A; Helin, C; Jeunemaitre, X; Namikawa, C; Nelson, L; Ogasawara, M; Suzumori, K; Tomoda, S; Ward, K, 1993) |
| "Preeclampsia is characterized by maternal hypercoagulable state and intravascular coagulation, microthromboses in several organs, and impairment of uteroplacental circulation." | ( Bruch, JF; Delarue, F; Flahault, A; He, CJ; Kanfer, A; Nessmann, C; Nguyen, G; Uzan, S, 1996) |
| "Preeclampsia is also characterized by increased free radical formation and elevated oxidative stress." | ( Hubel, CA; Many, A; Roberts, JM, 1996) |
| "Preeclampsia is a pregnancy-induced hypertensive disease." | ( Blombäck, M; Bremme, K, 1996) |
| "The pathogenesis of preeclampsia is proposed to be due to uncharacterized circulating factors that activate endothelial cells." | ( Davidge, ST; Hubel, CA; Lykins, DL; Roberts, JM; Signorella, AP, 1996) |
| "Preeclampsia is a disease which appears only during pregnancy." | ( Mejía, R; Sarto, A, 1996) |
| "Preeclampsia is a hypertensive disorder of human pregnancy that is a leading cause of premature delivery and fetal growth retardation." | ( Walsh, SW; Wang, Y, 1995) |
| "Preeclampsia is characterized by the triad of hypertension, proteinuria, and edema but these findings are not specific." | ( Suzuki, H, 1997) |
| "Preeclampsia is associated with altered biosynthesis of vasoactive prostanoids in placental villi." | ( Anteby, EY; Graham, C; Huang, X; Johnson, RD; Nelson, DM; Polakoski, KL; Sadovsky, Y, 1997) |
| "Preeclampsia is associated with a common molecular variant of angiotensinogen (Met235Thr)." | ( Craven, C; Lalouel, JM; Morgan, T; Nelson, L; Ward, K, 1997) |
| "Women with prior preeclampsia are characterized by hyperinsulinemia and a 2- to 3-fold excess risk of hypertension and ischemic heart disease in later life." | ( Kaaja, R; Laivuori, H; Rutanen, EM; Viinikka, L; Ylikorkala, O, 1998) |
| "The cause of preeclampsia is unknown, but may involve primary pathology at the maternal/fetal interface." | ( August, P; Baylis, C; Beinder, E; Sütö, T, 1998) |
| "Preeclampsia is a multisystemic obstetric disease of unknown etiology that is commonly associated with fibrin deposition, occlusive lesions in placental vasculature, and intrauterine fetal growth retardation." | ( Aznar, J; España, F; Estellés, A; Gilabert, J; Grancha, S; Loskutoff, DJ; Thinnes, T; Yamamoto, K, 1998) |
| "Preeclampsia is characterized by an increase in vascular tone associated with reduced uteroplacental flow." | ( Doering, TP; Freeman, EJ; Haller, NA; Hopkins, MP; Montgomery, MA, 1998) |
| "We concluded that preeclampsia is associated with an imbalance between lipid peroxides and the antioxidant system." | ( Ademoglu, E; Aykaç-Toker, G; Ibrahimoglu, L; Mutlu-Türkoglu, U; Uysal, M, 1998) |
| "Preeclampsia is a multisystem disorder of unknown etiology." | ( Sibai, BM, 1998) |
| "It was found that EPH gestosis is associated with a significant reduction of elastin content in the umbilical cord arteries as a result of decrease in elastin biosynthesis rate and accelerated degradation of this protein." | ( Bańkowski, E; Jaworski, S; Pawlicka, E, 1999) |
| "-Preeclampsia is a multisystemic disorder of pregnancy in which the normal vascular adaptations to pregnancy are compromised." | ( Davidge, ST; Roggensack, AM; Zhang, Y, 1999) |
| "Preeclampsia is associated with an increase in maternal plasma leptin concentrations that strongly correlates with the fetal cord concentration at delivery." | ( McCarthy, JF; Misra, DN; Roberts, JM, 1999) |
| "Preeclampsia is familial." | ( Morgan, T; Ward, K, 1999) |
| "Preeclampsia is a state of increased insulin resistance, and it persists for at least 3 months after pregnancy." | ( Kaaja, R; Laakso, M; Laivuori, H; Tikkanen, MJ; Ylikorkala, O, 1999) |
| "Preeclampsia is linked to sympathetic overactivity." | ( Andersen, RN; Egerman, RS; Manejwala, FM; Sibai, BM, 1999) |
| "Preeclampsia is characterized by reduced levels of estrogens and insulin-like growth factor-1, and by elevated levels of progesterone, androgens, human chorionic gonadotropin, IGF-1 binding protein, corticotropin-releasing factor, cortisol, and insulin." | ( Byers, TE; Innes, KE, 1999) |
| "As preeclampsia is characterized by inadequate trophoblast invasion, we investigated the hypothesis that decreased placental HGF production is a mechanism for inadequate trophoblast invasion in this disease." | ( Bae-Jump, V; Kauma, SW; Walsh, SW, 1999) |
| "Preeclampsia is associated with an abnormal lipid profile." | ( Audibert, F; Chalas, J; Claise, C; Francoual, J; Frydman, R; Lindenbaum, A; Trioche, P, 1999) |
| "Preeclampsia is primarily a disorder of the maternal endothelium." | ( Anthony, FW; Baker, PN; Brockelsby, JC; Johnson, IR, 2000) |
| "Animal models for preeclampsia are no alternative to clinical studies, but they are furthering our understanding of pathophysiology in many fields." | ( Casper, F; Hropot, M; Leiser, R; Seufert, R, 1999) |
| "Preeclampsia is a disease which occurs in Europe in about 6-8%, in the USA in about 7-10% and in Africa in about 18% of all pregnancies." | ( Bastert, G; Henschel, B; Schulz, M; Wacker, J; Werner, P, 1999) |
| "Preeclampsia is associated with a quantitative imbalance between lipid peroxide and an antioxidant coproduced in the placenta." | ( Honjo, H; Honma, T; Kashiwagi, T; Takanashi, K; Yoshizawa, I, 2000) |
| "Preeclampsia is still a leading cause of maternal and fetal morbidity and mortality." | ( Felfernig, M; Felfernig-Boehm, D; Husslein, P; Mittlboeck, M; Mueller, MR; Murabito, M; Salat, A; Schmidt, D; Vogl, SE, 2000) |
| "Preeclampsia is the pregnancy specific disorder in which reduced organ perfusion and ischemia of the kidney, liver and brain can be detected." | ( Semczuk, M; Semczuk-Sikora, A; Sikora, P, 2000) |
| "Preeclampsia is a mainly vascular disease of pregnancy, probably caused by an imbalance between vasodilator and vasoconstrictor agents that results in generalized vasospasm and poor perfusion in many organs." | ( Apa, R; Calce, A; Gulino, A; Lanzone, A; Miceli, F; Napolitano, M; Vacca, A, 2000) |
| "Preeclampsia is a multisystem disorder peculiar to human pregnancy." | ( Boer, K; Kublickiene, K; VanBavel, E; VanWijk, MJ, 2000) |
| "Preeclampsia is an important cause of maternal and perinatal mortality worldwide." | ( Bankson, DD; King, IB; Madzime, S; Mahomed, K; Mudzamiri, S; Williams, MA; Woelk, GB, 2000) |
| "Preeclampsia is associated with the imbalance between lipid peroxides and antioxidant nutrients (vitamin C and E)." | ( Panburana, P; Phuapradit, W; Puchaiwatananon, O, 2000) |
| "Preeclampsia is associated with an increased platelet activation; however, there are few studies concerning platelet activation of the newborn." | ( Amo-Takyi, BK; Faridi, A; Heilmann, L; Klein, B; Rath, W; Von Tempelhoff, GF, 2001) |
| "Preeclampsia is a pregnancy-specific disorder of humans which rates among one of the major cases of maternal and fetal morbidity and mortality." | ( Leszczyńska-Gorzelak, B; Oleszczuk, JJ; Szymczyk, G, 2000) |
| "The etiology of preeclampsia is still unknown." | ( Bolte, AC; Dekker, GA; van Geijn, HP, 2001) |
| "Preeclampsia is believed to result from release of placental factors that damage maternal vascular endothelium." | ( Chambers, JC; De Swiet, M; Fusi, L; Haskard, DO; Kooner, JS; Malik, IS, 2001) |
| "Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues." | ( Halvorsen, B; Henriksen, T; Ranheim, T; Sawamura, T; Staff, AC, 2001) |
| "Preeclampsia is associated with increased maternal and perinatal morbidity and mortality." | ( Bolte, AC; Dekker, GA; van Geijn, HP, 2001) |
| "Preeclampsia is associated with complex coagulation abnormalities that include altered platelet function and consumption and activation of the fibrinolytic system." | ( Bhavani-Shankar, K; Datta, S; Harnett, MJ, 2001) |
| "The pathogenesis of preeclampsia is not fully understood, and no specific diagnostic tests are available for early and reliable diagnosis, or for monitoring of the disease process." | ( Berg, S; Engman, A; Holmgren, S; Laurent, TC; Lundahl, T, 2001) |
| "Preeclampsia is known to be a multifactorial disease." | ( Fujimoto, S; Hata, A; Kanamori, M; Kato, EH; Kobashi, G; Kondo, K; Shido, K; Yamada, H, 2001) |
| "Preeclampsia is a potentially life-threatening disease for both mother and fetus." | ( Abyholm, T; Aukrust, P; Hestdal, K; Mellembakken, JR; Ueland, T; Videm, V, 2001) |
| "Preeclampsia is the main cause of maternal mortality and is associated with a five-fold increase in perinatal mortality in developing countries." | ( Casas, JP; López-Jaramillo, P; Serrano, N, 2001) |
| "Preeclampsia is the most common disease of pregnancy, occurring in up to 10% of the pregnant population." | ( Blyton, DM; Edwards, N; Kirjavainen, TT; Sullivan, CE, 2001) |
| "Preeclampsia is characterized by vasospasm, multiple organ hypoperfusion and endothelial cell damage." | ( Vural, P, 2002) |
| "Preeclampsia is a major complication during human pregnancy." | ( Laskowska, M; Leszczyńska-Gorzelak, B; Oleszczuk, J, 2001) |
| "PIH and preeclampsia are associated with minor alterations in antioxidant levels without signs of oxidative stress." | ( Berkelmans, R; Harren, FJ; Kateman, H; Nieuwenhuizen, A; Peters, WH; Raijmakers, MT; Steegers, EA; Steegers-Theunissen, RP; Stekkinger, E; Timmerman, BH; Zusterzeel, PL, 2002) |
| "Preeclampsia is a severe disorder of human pregnancy characterized by generalized activation of maternal endothelial cells." | ( Burton, GJ; Charnock-Jones, DS; Hung, TH; Skepper, JN, 2002) |
| "Preeclampsia is characterized by endothelial cell dysfunction, and lipid peroxidation and alterations of immune responses may be involved in the pathogenesis of this disease." | ( Araki, T; Doi, D; Otsubo, Y; Sawa, R; Suzuki, S; Yoneyama, K; Yoneyama, Y, 2002) |
| "Severe preeclampsia is a pathophysiological disorder specific to pregnancy and characterized by vasoconstriction and hypercoagulability." | ( Kanayama, N; Kobayashi, T; Naruse, H; Nishiguchi, T; Sugimura, M; Terao, T; Tokunaga, N, 2002) |
| "Preeclampsia is a multisystem disorder that complicates 6% to 8% of pregnancies, with higher rates in women with preexisting hypertension, diabetes mellitus, or previous history of preeclampsia." | ( Caritis, S; Hauth, J; Sibai, BM, 2003) |
| "Preeclampsia is considered to be a multifactorial and multisystemic disorder with a genetic predisposition." | ( Bouba, I; Georgiou, I; Kalaitzidis, R; Lolis, DE; Makrydimas, G; Siamopoulos, KC, 2003) |
| "Preeclampsia is a leading cause of maternal and neonatal mortality and morbidity." | ( Bilodeau, JF; Hubel, CA, 2003) |
| "Preeclampsia is associated with increased risk of adverse maternal (abruptio placentae, HELLP syndrome, eclampsia." | ( Desvaux, D; Haddad, B, 2003) |
| "Preeclampsia is a common complication of pregnancy and a significant cause of fetal and maternal morbidity and mortality." | ( Belfort, MA; Frias, AE, 2003) |
| "Preeclampsia is a common ( approximately 7% of all pregnancies) disorder of human pregnancy in which the normal hemodynamic response to pregnancy is compromised." | ( Calle, A; Escudero, C; Molina, G; Racines-Orbe, M; Teran, E; Vivero, S, 2003) |
| "Preeclampsia is a common and major cause of maternal and perinatal morbidity and mortality." | ( Al-Azemi, MK; Al-Qattan, F; Al-Yatama, M; Omu, AE, 2004) |
| "Preeclampsia is characterized by an imbalance between two cyclooxygenase metabolites of arachidonic acid, thromboxane and prostacyclin, that favors thromboxane." | ( Walsh, SW, 2004) |
| "Preeclampsia is a pregnancy-specific hypertensive disorder with unknown etiology, which affects 5% to 10% of all pregnancies." | ( Abdalla, S; Lother, H; Quitterer, U, 2004) |
| "Preeclampsia is associated with abnormal lipid metabolism, including fatty acid metabolism." | ( Aarnoudse, JG; Niezen-Koning, KE; Thiele, IG; van Gennip, AH, 2004) |
| "Preeclampsia is characterized by hypertension and proteinuria." | ( Beaufils, M; Carbillon, L; Challier, JC; Merviel, P; Rabreau, M; Uzan, S, 2004) |
| "Preeclampsia is a pregnancy disorder of unknown origin, characterized by vasospasm, elevated blood pressure, and increased neuromuscular irritability, features common to syndromes of magnesium deficiency." | ( Barbagallo, M; Bardicef, M; Bardicef, O; Cotton, DB; Dominguez, LJ; Evelhoch, J; Mason, BA; Resnick, LM; Sorokin, Y, 2004) |
| "Preeclampsia is associated with an imbalance between oxidants and antioxidants, resulting in reduced effects of the endothelium-derived, relaxing-factor nitric oxide (NO)." | ( Bisseling, TM; Maria Roes, E; Peters, WH; Raijmakers, MT; Smits, P; Steegers, EA, 2004) |
| "Preeclampsia is associated with a dysfunction of the NO-pathway." | ( Bisseling, TM; Maria Roes, E; Peters, WH; Raijmakers, MT; Smits, P; Steegers, EA, 2004) |
| "Preeclampsia is an inflammatory disorder in which serum levels of vascular endothelial growth factor (VEGF) and its soluble receptor-1 (sVEGFR-1, also known as sFlt-1) are elevated." | ( Ahmad, S; Ahmed, A, 2004) |
| "Preeclampsia is accompanied by an increase of collagen contents in the umbilical cord (UC) arteries and in Wharton's jelly." | ( Bańkowski, E; Galewska, Z; Gogiel, T; Jaworski, S; Romanowicz, L; Wolańska, M, 2005) |
| "Preeclampsia is associated with a distinct increase in the amount of this enzyme in the umbilical cord, whereas its activity deeply decreased." | ( Bańkowski, E; Galewska, Z; Gogiel, T; Jaworski, S; Romanowicz, L; Wolańska, M, 2005) |
| "Preeclampsia is associated with a reduction in the activity of cathepsin D in human umbilical cord." | ( Bańkowski, E; Galewska, Z; Gogiel, T; Jaworski, S; Romanowicz, L; Wolańska, M, 2005) |
| "Preeclampsia is one of the most serious complications of pregnancy." | ( Erel, O; Harma, M, 2005) |
| "Only severe form of preeclampsia is associated with oxidative stress which impaired placenta perfusion expressed by the increase of uterine arteries resistance." | ( Dubiel, M; Kornacki, J; Koźlik, J; Skrzypczak, J, 2004) |
| "Preeclampsia is a common and serious complication of pregnancy, characterized by maternal hypertension and proteinuria, placental insufficiency, and fetal growth restriction." | ( Hughes, AD; Regan, L; Thom, SA; Wimalasundera, RC, 2005) |
| "The incidence of preeclampsia is high in northern Nigeria, as it is in many other developing countries, and preeclampsia is associated with significant maternal and fetal morbidity and mortality." | ( Cole, DM; Crossey, MJ; El-Nafaty, AU; Glew, RH; Mehla, GS; Tzamaloukas, A; VanderJagt, DJ, 2005) |
| "Preeclampsia is the disorder of pregnancy with the highest rate of both maternal and neonatal morbidity and mortality." | ( Kelly, F; Poston, L; Raijmakers, M, 2004) |
| "Severe preeclampsia is defined by severe hypertension or massive proteinuria, with or without symptoms or altered laboratory tests." | ( Irion, O; Landau, R, 2005) |
| "Preeclampsia is accompanied by high fetal and maternal morbidity and mortality and to a high degree responsible for preterm delivery." | ( Diedrich, F; Fischer, T; Jacobs, VR; Neumaier-Wagner, P; Paepke, S; Pildner von Steinburg, S; Schneider, KT, 2005) |
| "Preeclampsia is a pregnancy-specific disease which is one of the leading causes of maternal and fetal morbidity and mortality." | ( Barak, S; Kreutzer, H; Machtei, EE; Oettinger, M; Oettinger-Barak, O; Ohel, G; Peled, M, 2005) |
| "Preeclampsia is characterized by pregnancy-induced hypertension accompanied with protein urea and generalized edema." | ( Itakura, A; Mizutani, S, 2005) |
| "Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology." | ( Albayrak, M; Aydin, S; Benian, A; Madazli, R; Topçuoğlu, MA; Uzun, H, 2005) |
| "Preeclampsia is an idiopathic multisystem disorder specific to human pregnancy." | ( Buhimschi, CS; Buhimschi, IA; Dorfman, DM; Fitzpatrick, PA; Norwitz, ER; Park, JS; Saade, GR; Tsen, LC, 2005) |
| "Even if preeclampsia is associated with an impairment of the ADRB3 responsiveness, ADRB3 agonists may have future pharmaceutical implications in the management of pregnancy-related disorders." | ( Advenier, C; Bardou, M; Barthez, O; Breuiller-Fouché, M; Cabrol, D; Dumas, M; Goirand, F; Guérard, P; Leroy, MJ; Morcillo, EJ; Rakotoniaina, Z; Rouget, C; Sagot, P, 2006) |
| "Preeclampsia is a common hereditary disease with unclear aetiology and various genetic and environmental components." | ( Heinonen, S; Helisalmi, S; Hiltunen, M; Laakso, M; Saarela, T, 2006) |
| "Preeclampsia is associated with oxidative stress, elevated plasma levels of linoleic acid (LA), and increased vascular smooth muscle expression of the inflammatory chemokine, interleukin-8 (IL-8)." | ( Leik, CE; Walsh, SW, 2005) |
| "Preeclampsia is a severe complication of human pregnancy often associated with maternal risk factors." | ( Gumaa, K; Kunjara, S; Paine, MA; Rademacher, TW; Rodeck, CH; Scioscia, M; Selvaggi, LE, 2006) |
| "Preeclampsia is a pregnancy-specific syndrome." | ( Berg, G; Ekerfelt, C; Ernerudh, J; Jonsson, Y; Matthiesen, L; Nieminen, K; Rubèr, M; Sharma, S, 2006) |
| "The onset of preeclampsia is associated with increased maternal insult that could affect placental function." | ( Beauséjour, A; Bibeau, K; Brochu, M; Lavoie, JC; St-Louis, J, 2007) |
| "Preeclampsia is associated with elevated plasma malondialdehyde concentration, but prospective data are scarce." | ( Bralley, JA; David, RM; Qiu, C; Rudra, CB; Walsh, SW; Williams, MA, 2006) |
| "Severe preeclampsia is characterized by increased fractional excretion of angiogenic factors and especially of vascular endothelial growth factor, likely reflecting 2 separate phenomena that may have additive effects: "endogenous" renal production and glomerular "leakage." | ( Buhimschi, CS; Buhimschi, IA; Funai, E; Guller, S; Kuczynski, E; Lockwood, CJ; Magloire, L; Martin, R; Norwitz, ER; Richman, S, 2006) |
| "Preeclampsia is a hypertensive disorder that is unique to pregnancy, with consistent involvement of the kidney." | ( Shah, DM, 2006) |
| "Preeclampsia is a disorder that continues to exact a significant toll with respect to maternal morbidity and mortality as well as fetal wastage." | ( Danchuk, S; Ianosi-Irimie, M; Pridjian, C; Pridjian, G; Puschett, JB; Vu, HV, 2006) |
| "Preeclampsia is associated with cardiovascular atherosclerotic events later in life." | ( Aarnoudse, JG; Blaauw, J; Fidler, V; Fokkema, MR; Smit, AJ; Van Doormaal, JJ; van Pampus, MG, 2006) |
| "Preeclampsia is a pregnancy-specific hypertensive syndrome that causes substantial maternal and fetal morbidity and mortality." | ( Bdolah, Y; D'Amore, PA; Epstein, FH; Hanai, J; Karumanchi, SA; Kim, YM; Lam, C; Letarte, M; Libermann, TA; Lim, KH; Mammoto, T; Roberts, D; Romero, R; Sellke, FW; Stillman, IE; Sukhatme, VP; Toporsian, M; Venkatesha, S; Yuan, HT, 2006) |
| "Preeclampsia is the second cause of maternal death in Ecuador." | ( Calle, A; Escudero, C, 2006) |
| "Preeclampsia is a disorder which is responsible for significant maternal morbidity and mortality as well as fetal wastage." | ( Puschett, JB, 2006) |
| "Preeclampsia is a common (approximately 7% of all pregnancies) disorder of pregnancy in which the normal hemodynamic response to pregnancy is compromised." | ( Castellanos, A; Chuncha, G; Enriquez, G; Moya, W; Racines-Orbe, M; Teran, E; Vivero, S, 2005) |
| "Preeclampsia is associated with profound vasoconstriction in most organ systems and reduced plasma volume." | ( Bruinse, HW; Delprat, CC; Elvan-Taşpinar, A; Franx, A; Koomans, HA, 2006) |
| "Preeclampsia is associated with oxidative stress in maternal circulation." | ( Braekke, K; Harsem, NK; Staff, AC, 2006) |
| "Preeclampsia is a syndrome of unknown etiopathogenesis." | ( Açikgoz, S; Can, M; Demirtas, S; Harma, M; Mungan, G, 2006) |
| "Preeclampsia is a disease characterized by hypertension and proteinuria but can manifest many abnormalities." | ( Graves, SW, 2007) |
| "Preeclampsia is a human pregnancy-specific disorder that is diagnosed by the new appearance of hypertension and proteinuria after 20 weeks' gestation." | ( Burton, GJ; Hung, TH, 2006) |
| "Preeclampsia is a pregnancy-specific hypertensive syndrome and a major cause of maternal and fetal morbidity and mortality." | ( D'Ambrosio, C; di Loreto, C; Fruscalzo, A; Marchesoni, D; Quadrifoglio, F; Salzano, AM; Scaloni, A; Tell, G; Vascotto, C, 2007) |
| "Preeclampsia is a pregnancy-specific disorder characterized by hypertension and proteinuria." | ( Garovic, VD; Grande, JP; Gray, CE; Hall, P; Kalluri, R; Petrovic, LM; Sugimoto, H; Wagner, SJ, 2007) |
| "Preeclampsia is associated with an increase of circulating levels of microparticles (MPs), but their role in vascular dysfunction during the course of preeclampsia is not understood." | ( Andriantsitohaina, R; Carusio, N; David, E; Kremer, H; Meziani, F; Schneider, F; Tesse, A, 2007) |
| "Preeclampsia is characterized clinically by hypertension and proteinuria." | ( Abbas, A; Ahmad, S; Ahmed, A; Al-Ani, B; Chudasama, K; Coxall, H; Cudmore, M; Devey, LR; Fujisawa, T; Hewett, PW; Wigmore, SJ, 2007) |
| "Preeclampsia is also associated with maternal thrombophilias and decidual hemorrhage, which form thrombin from decidual cell-expressed tissue factor." | ( Arcuri, F; Buchwalder, LF; Funai, EF; Huang, ST; Krikun, G; Lockwood, CJ; Norwitz, E; Schatz, F; Toti, P, 2007) |
| "Preeclampsia is a potentially fatal complication of human pregnancy characterized by hypertension, proteinuria, and edema." | ( Burton, GJ; Charnock-Jones, DS; Cindrova-Davies, T; Jauniaux, E; Spasic-Boskovic, O, 2007) |
| "Preeclampsia is a hypertensive disorder unique to pregnancy and remains the leading cause of maternal and fetal morbidity and mortality." | ( Escher, G; Mohaupt, M, 2007) |
| "Preeclampsia is the most common medical disorder of pregnancy." | ( Heilmann, L; Pollow, K; Rath, W, 2007) |
| "While preeclampsia is common in pregnancy, associated hyponatraemia is rare with very few cases reported in the literature." | ( Shutt, LE; Wilson, HJ, 2007) |
| "Preeclampsia is frequently related to generation of small for gestational age (SGA) infant especially in cases with severe preeclampsia." | ( Fujii, S; Itoh, H; Mise, H; Nuamah, MA; Sagawa, N; Takemura, M; Yura, S, 2007) |
| "Preeclampsia is defined as the association of pregnancy-induced hypertension and proteinuria of 300 mg/24h or more after 20 weeks gestation." | ( Tsasaris, V; Winer, N, 2008) |
| "Preeclampsia is characterized by intense and prolonged vasoconstriction." | ( Friel, AM; Hynes, PG; Morrison, JJ; Sexton, DJ; Smith, TJ, 2008) |
| "Preeclampsia is a pregnancy-associated illness affecting multiple organ systems." | ( Bremerich, DH; Fetsch, NI, 2008) |
| "Preeclampsia is a human syndrome characterized by elevated maternal blood pressure and proteinuria." | ( Escudero, C; Sobrevia, L, 2008) |
| "Preeclampsia is characterized by increased uPRL excretion." | ( Alvarez-Jiménez, G; Bermejo-Huerta, S; Cárdenas-Mondragón, GM; Chinolla-Arellano, ZL; Leaños-Miranda, A; Márquez-Acosta, J; Ramos-León, JC; Rivera-Leaños, R; Romero-Arauz, JF; Ulloa-Aguirre, A, 2008) |
| "Both smoking and preeclampsia are associated with alterations in circulating angiogenic factors." | ( Durica, AR; Harger, GF; Jeyabalan, A; Ness, RB; Powers, RW; Roberts, JM, 2008) |
| "Preeclampsia is a serious pathologic complication during pregnancy, and its pathogenesis remains poorly understood." | ( Chang, H; Cheng, X; Liu, H; Ma, XL; Wang, F; Wang, X; Yang, L; Yang, X; Zhang, M; Zhang, S, 2008) |
| "Preeclampsia is one such case." | ( Irani, RA; Xia, Y, 2008) |
| "Preeclampsia is a serious complication in pregnancy with an increased future cardiovascular risk for both mother and newborn." | ( Bluher, M; Ebert, T; Faber, R; Fasshauer, M; Lossner, U; Schrey, S; Seeger, J; Stepan, H; Stumvoll, M; Waldeyer, T, 2008) |
| "Preeclampsia is a major cause of maternal morbidity and mortality worldwide." | ( Carty, DM; Delles, C; Dominiczak, AF, 2008) |
| "Preeclampsia is pregnancy-specific, affecting 2% to 7% of women, and is a leading cause of perinatal and maternal morbidity and mortality." | ( Broughton Pipkin, F; Mistry, HD; Ramsay, MM; Symonds, ME; Wilson, V, 2008) |
| "Severe preeclampsia is the most common cause of liver dysfunction in pregnancy, and is in some cases further complicated by HELLP syndrome." | ( Blum, HE; Panther, E, 2008) |
| "Preeclampsia is a multisystem maternal and fetal syndrome." | ( Leeman, M, 2008) |
| "Preeclampsia is the major cause of maternal and fetal morbidity and mortality, involving 15% to 20% of pregnancies in developed countries and even more in less developed parts of the world." | ( Dechend, R; Luft, FC, 2008) |
| "Preeclampsia is one of the most common and severe pregnancy complications, which ethiology remains unclear." | ( Ivanov, S; Mazneĭkova, V; Stoĭkova, V; Tsoncheva, A, 2005) |
| "Preeclampsia is the most common pregnancy-associated pathological syndrome." | ( Bańkowski, E; Romanowicz, L, 2009) |
| "Preeclampsia is a pregnancy-specific disease characterised by maternal hypertension that is preceded by endothelial cell activation and an inappropriate inflammatory response." | ( Chamley, L; Chen, Q; Ching, LM; Jones, D; Stone, P, 2009) |
| "Preeclampsia is a common disorder of pregnancy exhibiting abnormal plasma and placental coenzyme Q10 (CoQ10) levels when compared to normal pregnancies." | ( Calle, A; Chedraui, P; Duchicela, F; Nacevilla, L; Racines-Orbe, M; Schwager, G; Teran, E; Villena, F; Vivero, S, 2008) |
| "Preeclampsia is a hypertensive disorder unique to pregnancy, in which the placenta may release factors into the maternal circulation resulting in systemic effects." | ( Davidge, ST; Sankaralingam, S; Sawamura, T; Xu, Y, 2009) |
| "Preeclampsia is the most common pregnancy-associated pathological syndrome." | ( Bańkowski, E; Romanowicz, L, 2009) |
| "Preeclampsia is one of the main causes of maternal and fetal mortality." | ( Kajdy, A; Niemiec, T, 2008) |
| "Preeclampsia is also associated with elevated endogenous digoxin-like factors (EDLFs)." | ( Adair, CD; Gu, Y; Kipikasa, JH; Lewis, DF; Mason, L; Wang, Y, 2009) |
| "Severe preeclampsia is associated with significantly lower erythrocyte sodium pump activity than normotensive pregnancy." | ( Adair, CD; Buckalew, V; Haupert, GT; Koh, HP; Veille, JC; Wang, Y, 2009) |
| "Preeclampsia is a hypertensive disorder which develops de novo in women during pregnancy." | ( Childs, EW; Horvat, D; Hunter, FA; McLean, LB; Puschett, JB; Severson, J; Tharakan, B; Uddin, MN, 2009) |
| "As preeclampsia is characterized by heightened inflammation, oxidative stress, and hyperuricemia, it has been proposed that xanthine oxidase plays a pivotal role in this hypertensive disorder of pregnancy." | ( Bainbridge, SA; Deng, JS; Roberts, JM, 2009) |
| "Preeclampsia is a disease associated with the maternal inflammatory response." | ( Hong, SC; Jeong, NH; Jung, SE; Kim, HJ; Lee, ES; Lim, JE; Oh, MJ; Park, SH; Seol, HJ, 2009) |
| "Preeclampsia is a major pregnancy-specific disorder affecting 5-7% of pregnancies worldwide." | ( Chang, CW; Chen, CP; Chen, H; Cheong, ML; Chiang, MH; Chou, CC; Liang, CY; Liang, FY; Lin, FY; Wang, LJ, 2009) |
| "Preeclampsia is a life-threatening hypertensive disease of pregnancy." | ( Kellems, RE; Xia, Y, 2009) |
| "Preeclampsia is a serious pregnancy complication, accompanied by increased maternal and fetal morbidity." | ( Carlström, M; Eriksson, UJ; Persson, AE; Skøtt, O; Wentzel, P, 2009) |
| "Preeclampsia is a major obstetric problem of unknown etiology." | ( Akerström, B; Centlow, M; Hansson, SR; Junus, K; Larsson, I; May, K; Nyström, H; Olsson, MG; Sager, R; Schneider, H, 2009) |
| "Preeclampsia is associated with widespread maternal vascular dysfunction, which is thought to be mediated by circulating factor(s)." | ( English, FA; Johns, EJ; Kenny, LC; Walsh, SK, 2009) |
| "Preeclampsia is a big problem in obstetrics." | ( Wiwanitkit, V, 2010) |
| "Preeclampsia is a leading cause of intrauterine growth restriction and preterm birth." | ( Braekke, K; Harsem, NK; Staff, AC; Ueland, PM, 2009) |
| "Preeclampsia is a leading cause of maternal and fetal/neonatal mortality and morbidity worldwide." | ( Grill, S; Hahn, S; Holzgreve, W; Lapaire, O; Rusterholz, C; Tercanli, S; Zanetti-Dällenbach, R, 2009) |
| "Preeclampsia is a hypertensive disorder characterized by vascular oxidative stress." | ( Davidge, ST; Sankaralingam, S; Xu, H, 2010) |
| "Preeclampsia is characterized by vascular endothelial dysfunction partly attributed to oxidative stress." | ( Davidge, ST; Jiang, Y; Sankaralingam, S; Sawamura, T; Xu, H, 2009) |
| "Preeclampsia is referred to as the "disease of the theories" because of the multiple hypotheses proposed to explain is occurrence." | ( Kutlesić, R; Milosavljević, M; Popović, J; Stefanović, M; Tubić-Pavlović, A; Vukomanović, P, 2009) |
| "Preeclampsia is the major cause of maternal and fetal mortality/morbidity." | ( Cloutier, G; Falcao, S; Gutkowska, J; Lavoie, JL; Maurice, RL; Stoyanova, E, 2009) |
| "Preeclampsia is a major cause of maternal and neonatal morbidity and mortality worldwide." | ( Böger, RH; Diemert, A; Hecher, K; Lüneburg, N; Maas, R; Schwedhelm, E, 2010) |
| "Preeclampsia is characterized by increased lipid peroxidation and diminished antioxidant capacity; however, there is no consensus as to the extent of these conditions." | ( Agarwal, A; Agarwal, R; Aziz, N; Gupta, S; Li, J; Mansour, G; Sekhon, L, 2009) |
| "Established preeclampsia is associated with increased concentrations of oxidative stress markers including lipid peroxidation products, and a reduction in antioxidant concentrations." | ( Agarwal, A; Agarwal, R; Aziz, N; Gupta, S; Li, J; Mansour, G; Sekhon, L, 2009) |
| "Preeclampsia is associated with a slight increase in the total fatty acid content in Wharton's jelly and with marked changes in the proportional relationships between various lipids." | ( Bańkowski, E; Romanowicz, L, 2010) |
| "Preeclampsia is a major cause of maternal and fetal mortality, and its pathogenesis is not fully understood." | ( Bagrov, AY; Bzhelyansky, AM; Fedorova, OV; Frolova, EV; Kashkin, VA; Nikitina, ER; Reznik, VA; Tapilskaya, NI, 2010) |
| "Preeclampsia is a major global cause of maternal, neonatal and perinatal mortality." | ( Bujold, E; Forest, JC; Giguère, Y; Lacasse, Y; Morency, AM; Roberge, S, 2009) |
| "Preeclampsia is a hypertensive disorder unique to pregnancy in which elevated levels of marinobufagenin (MBG) have been reported." | ( Agunanne, E; Horvat, D; Puschett, JB; Uddin, MN, 2010) |
| "Preeclampsia is a major complication of pregnancy that can lead to substantial maternal and perinatal morbidity, mortality, and preterm birth." | ( Chung, J; Delfino, RJ; Ren, C; Ritz, B; Wilhelm, M; Wu, J, 2009) |
| "Preeclampsia is a major cause of maternal and perinatal morbidity and mortality, but its cause is poorly understood." | ( Hughes, AD; Regan, L; Thom, SM; Wijetunge, S; Wimalasundera, RC, 2010) |
| "Preeclampsia is a complex obstetrical syndrome characterized by hypertension and proteinuria." | ( Bélanger, MC; Berthiaume, L; Bilodeau, JF; Boutet, M; Fraser, WD; Gagné, A; Julien, P; Roland, L, 2010) |
| "Preeclampsia is the most common pregnancy-associated pathological syndrome." | ( Bańkowski, E; Romanowicz, L, 2010) |
| "Preeclampsia is characterized by a disruption of general vascular dilatation, which is mainly mediated by nitric oxide (NO) and disturbed by reactive oxygen species (ROS)." | ( Hyodo, S; Ito, M; Katayama, T; Matsubara, K; Matsubara, Y, 2010) |
| "Preeclampsia is a disease hypothesized to originate from widespread endothelial dysfunction or damage." | ( Duvekot, JJ; Gratama, JW; Kraan, J; Lamers, CH; Snijder, CA; Strijbos, MH, 2010) |
| "Preeclampsia is characterized by endothelial dysfunction and activation rather than actual endothelial damage as characterized by increased CEC counts." | ( Duvekot, JJ; Gratama, JW; Kraan, J; Lamers, CH; Snijder, CA; Strijbos, MH, 2010) |
| "Preeclampsia is a debilitating disorder affecting approximately 3% of pregnant women in the Western world." | ( Gjessing, HK; Jugessur, A; Lie, RT; Nilsen, ST; Vefring, HK; Wee, L, 2010) |
| "Preeclampsia is associated with increased systemic inflammation and superficial trophoblast invasion, which leads to insufficient uteroplacental blood flow." | ( Arda, O; Basar, M; Buchwalder, LF; Godlewski, K; Huang, SJ; Kayisli, UA; Kocamaz, E; Lockwood, CJ; Murk, W; Schatz, F; Yen, CF, 2010) |
| "Preeclampsia is characterized by hypertension and proteinuria developing after 20 weeks of gestation." | ( Cachina, T; Foudi, N; Gezer, A; Kucur, M; Madazli, R; Norel, X; Ozdemir, O; Topal, G; Uydes-Dogan, BS, 2010) |
| "Preeclampsia is associated with increased risk of cardiovascular disease." | ( de Vries, JI; van der Horst, M; van Weissenbruch, MM, 2011) |
| "Preeclampsia is a major cause of maternal and neonatal morbidity and mortality." | ( Burmeister, MA; D'Agati, VD; Davisson, RL; Qing, X; Redecha, PB; Salmon, JE; Tomlinson, S, 2011) |
| "Preeclampsia is a serious pregnancy-specific complication that results in high maternal and neonatal mortality and morbidity worldwide." | ( Hu, Y; Shen, Y; Zhang, Y, 2011) |
| "Preeclampsia is one of the leading causes of obstetric morbidity and mortality." | ( Kukor, Z; Valent, S, 2010) |
| "Preeclampsia is a relatively common pregnancy-related disorder." | ( Hasuwa, H; Ikawa, M; Kidoya, H; Kimura, T; Kumasawa, K; Morioka, Y; Okabe, M; Saito-Fujita, T; Takakura, N, 2011) |
| "Preeclampsia is a condition of a lack of UA Endo adaptation and poor NO production/vasodilation and is associated with elevated placental VEGF(165)." | ( Bird, IM; Boeldt, DS; Magness, RR; Yi, FX, 2011) |
| "The incidence of preeclampsia is reduced by a third in smokers, but not in snuff users." | ( Ahmed, A, 2011) |
| "Preeclampsia is associated with hyperuricemia, which correlates with the disease severity." | ( Abrahams, VM; Boeras, C; Guller, S; Kavathas, PB; Mulla, MJ; Myrtolli, K; Norwitz, ER; Potter, J; Sfakianaki, AK; Tadesse, S, 2011) |
| "We conclude that preeclampsia is associated with decreased levels of NO and increased levels of circulating inflammatory cytokines due to single nucleotide polymorphisms, pointing toward the role of endothelial and inflammatory components." | ( Bhattacharjee, J; Sharma, D; Singh, A; Trivedi, SS, 2011) |
| "Preeclampsia is a disorder resulting in significant fetomaternal complications with no definitive pharmacological intervention." | ( Agunanne, E; Berghman, LR; Ghanem, DA; Harrison, R; Horvat, D; Jones, R; Kuehl, TJ; Lai, X; Li, J; Puschett, JB; Romo, D; Uddin, MN, 2011) |
| "Preeclampsia is a leading cause of maternal mortality, and early-onset preeclampsia can result in serious long-lasting consequences to the neonate." | ( Everett, TR; Lees, CC; Wilkinson, IB, 2012) |
| "Preeclampsia is a major cause of pregnancy morbidity and mortality." | ( Chamley, LW; Chen, Q; Liu, B; Liversidge, XL; Stone, P, 2011) |
| "Preeclampsia is frequently accompanied by fetal growth restriction (FGR)." | ( Fujimaki, A; Kimura, C; Mori, T; Shinohara, K; Wakatsuki, A; Watanabe, K, 2011) |
| "Preeclampsia is a pregnancy-induced hypertensive disorder found most commonly in nulliparous women." | ( George, EM; Granger, JP, 2011) |
| "Preeclampsia is an important cause of maternal and perinatal mortality worldwide." | ( Abutorabi, S; Jaliseh, HK; Ranjkesh, F, 2011) |
| "Preeclampsia is associated with abnormal calcium metabolism and placental dysfunction." | ( Akierman, AR; Al-Awad, E; Finch, RA; Hasan, SU; Kamaluddeen, M; Yusuf, K, 2012) |
| "The pathogenesis of preeclampsia is unclear but is thought to be related to shallow trophoblast invasion." | ( Chen, LL; Feng, YJ; Lu, M; Qiao, QQ; Sun, YY; Xi, XW; Xu, XM, 2011) |
| "Preeclampsia is a pregnancy-induced hypertensive disorder characterized by proteinuria and widespread maternal endothelial dysfunction." | ( George, EM; Granger, JP, 2011) |
| "Preeclampsia is a multisystemic disorder of pregnancy characterized by hypertension, proteinuria, and maternal endothelial dysfunction." | ( Drewlo, S; Johns, EJ; Kenny, LC; Kingdom, J; McCarthy, FP; Walsh, SK, 2011) |
| "Oxidative stress in preeclampsia is the result of the increase in reactive oxygen species and of the decrease in antioxidants." | ( Ciortea, R; Costin, N; Măluţan, A; Mihu, CM; Mihu, D; Sabău, L, 2012) |
| "Preeclampsia is characterized by hypertension and proteinuria that begins in the second half of pregnancy." | ( Acikgoz, S; Can, M; Guven, B; Harma, M; Mungan, G; Sancar, E, 2011) |
| "Preeclampsia is a disease regarding with altered vascular reactivity leading to hypertension of the mother and metabolic alterations in the fetus." | ( Hosseini-khah, Z; Moslemizade, N; Rafiei, A; Yazdani, F; Yusefnezhad, K, 2011) |
| "Preeclampsia is one of hypertensive disorders in pregnancy." | ( Ma, RQ; Sun, MN; Yang, Z, 2011) |
| "Preeclampsia is a syndrome characterized by hypertension and proteinuria." | ( Akalin, S; Akgul, EO; Alacam, H; Aydin, I; Cakir, E; Danisman, N; Deren, O; Dikmen, ZG; Dogan, P; Keskin, U; Kurt, YG; Polat, B; Yaman, H, 2011) |
| "Preeclampsia is associated with systemic inflammation and increased expression of placental Th1-cytokines." | ( Avila, E; Barrera, D; Díaz, L; Halhali, A; Larrea, F; Noyola-Martínez, N, 2012) |
| "Preeclampsia is associated with increased risk of cardiovascular disease." | ( Dechend, R; Hering, L; Herse, F; Mockel, M; Staff, AC; Sugulle, M, 2012) |
| "The hallmark of preeclampsia is similar to the toxicities related to antiangiogenesis therapy." | ( Haruta, S; Kobayashi, H; Nagai, A; Naruse, K; Noguchi, T; Sado, T; Tanase, Y; Tsunemi, T; Yoshida, S, 2012) |
| "Preeclampsia is a pregnancy specific disorder connected with endothelial cell dysfunction." | ( Padmini, E; Uthra, V, 2012) |
| "Preeclampsia is a serious pregnancy complication." | ( Fraser, WD; Luo, ZC; Wu, Y; Xiong, X, 2012) |
| "Preeclampsia is a major cause of maternal and fetal morbidity and mortality that has been associated with endothelial dysfunction attributed, in part, to dyslipidemia, an imbalance in angiogenic factors and oxidative stress." | ( Abdalvand, A; Davidge, ST; Jiang, Y; Morton, JS; Sawamura, T; Uwiera, RR, 2012) |
| "The women with preeclampsia are more insulin resistant than those with normal pregnancy." | ( Amaliev, G; Dimitrakova, E; Mladenova, M; Pehlivanov, B, 2011) |
| "Preeclampsia is defined as new-onset hypertension with proteinuria after 20 wk gestation and is hypothesized to be due to shallow trophoblast invasion in the spiral arteries thus resulting in progressive placental ischemia as the fetus grows." | ( LaMarca, B; Li, J; Reckelhoff, JF, 2012) |
| "Preeclampsia is a common complication of pregnancy associated with high maternal morbidity and mortality and intrauterine fetal growth restriction." | ( Eiland, E; Faulkner, M; Nzerue, C, 2012) |
| "Preeclampsia is a disorder of hypertension and proteinuria that affects 6 - 8% of normal pregnancies." | ( Craici, IM; Garovic, VD; Grande, JP; Wagner, SJ, 2012) |
| "Preeclampsia is a pregnancy-specific disorder characterized by hypertension and systemic endothelial dysfunction." | ( Amash, A; Holcberg, G; Huleihel, M; Sapir, O, 2012) |
| "Preeclampsia is an inflammatory condition, involving the pregnant mother and complicated by the presence of a growing child and a disfunctional placenta; such is its complexity that so far no one has been able to fully elucidate its pathophysiology." | ( Crotty, TP, 2012) |
| "Preeclampsia is a serious complication of pregnancy, which is the cause of 60 000 maternal deaths annually worldwide." | ( Savaj, S; Vaziri, N, 2012) |
| "Preeclampsia is associated with urinary excretion of plasmin(ogen) and plasmin-dependent activation of ENaC by urine." | ( Bistrup, C; Buhl, KB; Frederiksen-Møller, B; Friis, UG; Gulaveerasingam, A; Jensen, BL; Jespersen, B; Ovesen, P; Svenningsen, P, 2012) |
| "Preeclampsia is associated with shallow trophoblast invasion and inadequate spiral artery remodeling, which are widely believed to lead to placental hypoxia, the putative culprit initiating the cascade of events that ultimately results in the maternal manifestations of the disease." | ( Tal, R, 2012) |
| "Preeclampsia is a significant cause of maternal and fetal morbidity and mortality worldwide." | ( Baelde, HJ; Bloemenkamp, KW; Bruijn, JA; Cohen, D; Kelder, TP; Penning, ME; Scherjon, SA; Uh, HW, 2012) |
| "Preeclampsia is a unique life-threatening disorder of human pregnancy associated with the abnormal placentation caused by the inadequate trophoblastic invasion due to altered apoptosis of these cells." | ( Bhatla, N; Dhingra, R; Kumar, R; Sharma, M, 2012) |
| "Preeclampsia is a multisystem disorder of pregnancy, originating in the placenta." | ( Brewer, J; Dechend, R; Ekholm, E; Gauster, M; Herse, F; Hoyer, J; Hubel, CA; Huppertz, B; Kaartokallio, T; Kacik, M; Laivuori, H; Lamarca, B; Lokki, AI; Luft, FC; Muller, DN; Novotny, S; Park, JK; Rothe, M; Ryan, MJ; Schunck, WH; Staff, AC; Sugulle, M; Verlohren, S; Wallukat, G, 2012) |
| "Preeclampsia is a pregnancy-specific disease characterized by hypertension, proteinuria, and oxidative stress in the placenta." | ( An, BS; Choi, KC; Jeung, EB; Kim, JM; Kim, TH; Lee, HH; Yang, H, 2013) |
| "Preeclampsia is the leading cause of maternal and fetal morbidity and mortality during pregnancy." | ( Herse, F; LaMarca, B, 2013) |
| "Preeclampsia is a leading cause of maternal and fetal morbidity/mortality; however, the pathophysiological mechanisms are unclear." | ( Abdalvand, A; Bourque, SL; Davidge, ST; Morton, JS; Quon, AL, 2013) |
| "Severe early onset preeclampsia is one of the most serious complications of pregnancy." | ( Kaitu'u-Lino, TJ; Macintire, K; Palmer, K; Skubisz, M; Tong, S; Tuohey, L; Ye, L, 2013) |
| "Preeclampsia is a major disorder of pregnancy and a leading cause of maternal and perinatal morbidity and mortality." | ( Fu, G; Ji, L; Lye, S; Manchanda, T; Nadeem, L; Peng, C; Qiao, J; Wang, Y; Wang, YL; Yang, BB; Ye, G; Zhao, Y, 2013) |
| "Preeclampsia is a pregnancy-specific condition characterized by an imbalance of circulating angiogenic factors and new-onset hypertension." | ( Banek, CT; Bauer, AJ; Capoccia, S; Gilbert, JS; Gillham, H; Needham, K; Regal, JF, 2013) |
| "Preeclampsia is associated with elevated natriuretic peptide levels." | ( Afshani, N; Biccard, BM; Dyer, RA; Moustaqim-Barrette, A; Rodseth, RN, 2013) |
| "Preeclampsia is associated with disturbed renal function, overproduction of cytokines and vasoregulatory factors, and fetal growth restriction." | ( Gad, HI, 2013) |
| "Preeclampsia is a complication of pregnancy that is marked by hypertension, proteinuria, and maternal endothelial dysfunction." | ( Dent, EA; George, EM; Granger, JP; Palei, AC, 2013) |
| "Preeclampsia is characterized by maternal systemic anti-angiogenic and pro-inflammatory states." | ( Bhatti, G; Chaiworapongsa, T; Dong, Z; Fule, T; Hassan, SS; Karaszi, K; Kovalszky, I; Krenacs, T; Papp, Z; Romero, R; Szabo, S; Tarca, AL; Than, NG; Varkonyi, I; Varkonyi, T; Xu, Y, 2013) |
| "Preeclampsia is a life-threatening pregnancy disorder." | ( Hu, Y; Mata-Greenwood, E; Paradis, A; Wang, Z; Xiao, D; Zhang, L; Zhou, J, 2013) |
| "Preeclampsia is a leading cause of maternal and fetal mortality and morbidity." | ( Chamley, LW; Chen, Q; Snowise, S; Stone, PR; Tong, M; Wu, M, 2013) |
| "Preeclampsia is a disease with great variability in incidence across the world." | ( Araújo, AC; Azevedo, Mde F; Dantas, DL; Dantas, EM; Duggal, P; Jeronimo, SM; Monteiro, GR; Pereira, FV; Queiroz, JW, 2013) |
| "Preeclampsia is associated with elevated blood pressure, inflammation and endothelial dysfunction, and these findings remain 1 year after delivery." | ( Al-Nashi, M; Bremme, K; Eriksson, M; Hamad, RR; Kahan, T; Larsson, A; Östlund, E, 2013) |
| "Hypertension during preeclampsia is associated with increased maternal vascular sensitivity to angiotensin II (ANGII)." | ( Brewer, J; Dechend, R; Herse, F; Lamarca, B; Liu, R; Lu, Y; Martin, JN; Moseley, J; Scott, J; Wallace, K; Wallukat, G, 2013) |
| "A hallmark of preeclampsia is endothelial cell dysfunction/activation in response to "toxins" from the placenta." | ( Chamley, LW; Chen, Q; Snowise, S; Stone, P; Tong, M; Wu, M; Zhang, Y, 2013) |
| "Preeclampsia is a life-threatening pregnancy disorder that is widely thought to be triggered by impaired placental development." | ( Blackwell, SC; Irani, RA; Jin, J; Kellems, RE; Liu, C; Parchim, N; Sibai, B; Wang, W; Xia, Y, 2014) |
| "The incidence of preeclampsia is between 3% and 10% ofpregnancies." | ( Malinova, M; Paskaleva, V, 2013) |
| "Preeclampsia is a life-threatening disorder of pregnancy." | ( Altun, B; Aybal-Kutlugun, A; Erdem, Y; Kucukozkan, T; Yildirim, T; Yilmaz, R; Yilmaz, Z, 2015) |
| "Preeclampsia is a multi systemic syndrome of variable severity, pregnancy specific, consequence of an abnormal vascular response to placentation, with increase in peripheral vascular resistance, stimulation of platelet aggregation, activation of the coagulation cascade, and endothelial dysfunction." | ( Castelazo-Alatorre, S; Castelazo-Morales, E; López-Rioja, Mde J; Monzalbo-Núñez, DE, 2014) |
| "Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality." | ( Henderson, JT; O'Connor, E; Rowland, MG; Senger, CA; Thompson, JH; Whitlock, EP, 2014) |
| "Preeclampsia is an important cause of maternal and perinatal morbidity and mortality." | ( Atallah, AN; Kulay, L; Santos, GM; Sass, N; Souza, EV; Torloni, MR, 2014) |
| "Preeclampsia is associated with alterations in the maternal renin-angiotensin-aldosterone system (RAAS), increased blood pressure (BP), and cardiovascular risk in the offspring." | ( Brosnihan, KB; Chappell, MC; Diz, DI; Gwathmey, TM; Nixon, PA; O'Shea, TM; Russell, GB; Snively, BM; Washburn, LK, 2015) |
| "Preeclampsia is a human pregnancy-specific disorder characterized by a placental pro-inflammatory response in combination with an imbalance of angiogenic factors and clinical symptoms, including hypertension and proteinuria." | ( Albrecht, C; Aliyev, E; Baumann, M; Brownbill, P; Hediger, M; Jain, A; Schneider, H; Soydemir, F; Surbek, D, 2014) |
| "As preeclampsia is associated with specific renal pathology including podocyte injury, early urinary podocyte (podocyturia), or the podocyte specific proteinuria nephrin in the urine (nephrinuria), as well as the more easily measured urinary albumin (albuminuria), have all been suggested as predictive markers." | ( Cohen, HW; He, JC; Jim, B; Kim, K; Mehta, S; Moore, RM; Qipo, A; Sharma, S, 2014) |
| "Preeclampsia is a pregnancy-specific disorder of unknown etiology and a leading contributor to maternal and perinatal morbidity and mortality worldwide." | ( Bernstein, IM; Buhimschi, CS; Buhimschi, IA; Funai, EF; Glabe, CG; Nayeri, UA; Pensalfini, A; Shook, LL; Zhao, G, 2014) |
| "Preeclampsia is one of the major cause of maternal morbidity and mortality." | ( Jameil, NA, 2014) |
| "Preeclampsia is a serious pregnancy complication." | ( Brownfoot, FC; Hannan, N; Kaitu'u-Lino, T; Onda, K; Tong, S, 2014) |
| "Preeclampsia is a severe pregnancy-related disorder and a leading cause of maternal and fetal mortality worldwide." | ( Bühler, M; Lalevée, S; Lapaire, O, 2014) |
| "Preeclampsia is associated with oxidative stress, which is suspected to play a role in hypertension, placental ischemia, and fetal demise associated with the disease." | ( Chatman, K; Cornelius, DC; Heath, J; LaMarca, B; Moseley, J; Scott, J; Wallace, K, 2014) |
| "Preeclampsia is characterized by increased uterine artery resistance index, chronic immune activation, and decreased circulating nitric oxide levels." | ( Amaral, LM; Cornelius, DC; Harmon, A; LaMarca, B; Martin, JN; Moseley, J, 2015) |
| "Preeclampsia is a pregnancy-specific condition affecting 2-7% of women and a leading cause of perinatal and maternal morbidity and mortality." | ( Chappell, LC; Gill, CA; Hesketh, JE; Kurlak, LO; Méplan, C; Mistry, HD; Morgan, L; Poston, L; Schomburg, L; Seed, PT, 2015) |
| "Preeclampsia is a disorder of pregnancy with a significant impact on maternal and fetal health." | ( Cheung, PY; Davidge, ST; Morton, JS; Quon, A; Sawamura, T, 2015) |
| "Preeclampsia is a pregnancy-specific disease characterized by concurrent development of hypertension, proteinuria, and oxidative stress in the placenta." | ( Ahn, C; Jeung, EB; Yang, H, 2015) |
| "Preeclampsia is an autoimmune disorder characterized by hypertension." | ( Celec, P; Konečná, B; Vlková, B, 2015) |
| "Preeclampsia is a prevalent hypertensive disorder of pregnancy and a leading cause of maternal and neonatal morbidity and mortality worldwide." | ( Blackburn, MR; Blackwell, SC; Chan, LN; Chan, TS; Hart, LA; Hicks, MJ; Iriyama, T; Kellems, RE; Li, J; Parchim, NF; Sibai, BM; Song, A; Sun, K; Xia, Y; Zhao, C, 2015) |
| "Preeclampsia is responsible for more than one-third of all maternal deaths in Brazil." | ( Colli, C; de Sousa Rocha, V; Della Rosa, FB; Ruano, R; Zugaib, M, 2015) |
| "Preeclampsia is associated with impaired placental vasodilation and reduced endothelial nitric oxide synthase (eNOS) activity in the foetoplacental circulation." | ( Bugueño, K; Farías, M; Guzmán-Gutiérrez, E; Leiva, A; Mate, A; Pardo, F; Ramírez, MA; Sáez, T; Salsoso, R; Sanhueza, C; Sobrevia, L; Vázquez, C, 2015) |
| "Preeclampsia is associated with developmental delay in infants and with an increased risk of various diseases in adulthood, including hypertension and epilepsy." | ( Gu, W; Hu, R; Kang, Y; Li, X; Liu, H; Liu, X; Ye, C; Zhao, W, 2016) |
| "Preeclampsia is a severe complication of pregnancy, characterized by hypertension, oxidative stress, and severe endothelial dysfunction." | ( Beard, S; Binder, N; Brownfoot, F; Hannan, NJ; Hirano, T; Kaitu'u-Lino, T; Kondo, M; Monchusho, H; Nakahara, A; Onda, K; Tong, S; Tuohey, L, 2015) |
| "Preeclampsia is a multisystem disease of pregnancy which is characterised by hypertension and involvement of one or more organ systems." | ( Balson, IF; Dennis, AT; Ozcan, J, 2015) |
| "Preeclampsia is a cardiovascular (CV) disease risk factor, and lifestyle modifications are recommended." | ( Acmaz, G; Afsar, B; Aykas, F; Bulut, K; Covic, A; Dogan, S; Erden, A; Johnson, RJ; Kanbay, M; Sarli, B; Sharma, S; Siriopol, D; Solak, Y, 2015) |
| "Preeclampsia is a major cause of maternal and perinatal mortality and morbidity." | ( Zhang, AK, 2015) |
| "Preeclampsia is a syndrome occurring only in pregnancy characterized by systemic maternal inflammation and associated with the presence of the placenta." | ( Ferguson, BJ; Hartley, JD; Moffett, A, 2015) |
| "Preeclampsia is a pregnancy specific hypertensive disease that confers significant maternal and fetal risks." | ( Anton, L; Elovitz, MA; Hogenesch, JB; Olarerin-George, AO, 2015) |
| "Preeclampsia is a serious pregnancy complication characterized by hypertension, proteinuria with or without pathological edema." | ( Khatiwada, B; Pradhan, P; Pramanik, T, 2014) |
| "Preeclampsia is a devastating cardiovascular disorder of late pregnancy, affecting 5-7% of all pregnancies and claiming the lives of 76,000 mothers and 500,000 children each year." | ( Devor, EJ; Gibson-Corley, KN; Grobe, JL; Pierce, GL; Sandgren, JA; Santillan, DA; Santillan, MK; Scroggins, SM; Sigmund, CD, 2015) |
| "Preeclampsia is a unique disease of pregnancy." | ( Jiang, lH; Li, L; Liu, B; Wang, T; Wei, XY; Zhu, JB, 2015) |
| "Preeclampsia is characterized by generalized endothelial dysfunction and impaired maternal tissue perfusion, and insulin resistance is a prominent feature of this disease." | ( Anim-Nyame, N; Gamble, J; Johnson, MR; Sooranna, SR; Steer, PJ, 2015) |
| "Preeclampsia is one of the most serious pregnancy-related diseases and clinically manifests as hypertension and proteinuria after 20 gestational weeks." | ( Åkerström, B; Axelsson, J; Casslén, V; Erlandsson, L; Gram, M; Hansson, SR; Johansson, M; Larsson, I; Mörgelin, M; Nääv, Å; Wester-Rosenlöf, L, 2015) |
| "Preeclampsia is a common disorder of human pregnancy and a major cause of worldwide pregnancy-related maternal and neonatal morbidity and mortality." | ( Athanasiadis, A; Kourtis, A; Makedou, K; Masoura, S; Theodoridis, T; Zepiridis, L, 2015) |
| "Preeclampsia is a systemic vascular disorder of pregnancy and is associated with increased sensitivity to angiotensin II (AngII) and hypertension." | ( Arnolda, LF; Burchell, J; Charles, AK; Chong, YS; Ganss, R; He, B; Holobotovskyy, V; Leader, L; McKitrick, DJ; Murphy, TV; Phillips, M; Sandow, SL; Tare, M, 2015) |
| "Preeclampsia is a multifactorial disease during pregnancy." | ( Ding, XY; Han, YW; Yang, Z; Yu, H, 2015) |
| "Worldwide, preeclampsia is a significant health risk to both pregnant women and their unborn children." | ( Agrawal, DK; Kirkpatrick, DR; Kovilam, O; Smith, TA, 2015) |
| "Preeclampsia is a disorder of pregnancy characterized by endothelial activation." | ( Chamley, L; Chen, Q; DeSousa, J; Stone, P; Tong, M; Wei, J, 2016) |
| "Preeclampsia is a serious complication of pregnancy with no medical treatment." | ( Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Kaitu'u-Lino, TJ; Tong, S; Tuohey, L, 2015) |
| "Preeclampsia is a major pregnancy complication where excess placental release of soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin causes maternal endothelial and multisystem organ injury." | ( Binder, NK; Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Kaitu'u-Lino, TJ; Onda, K; Tong, S; Walker, SP, 2015) |
| "Preeclampsia is a pregnancy disease characterized by hypertension and proteinuria." | ( Barrera, D; Díaz, L; Halhali, A; Noyola-Martínez, N, 2015) |
| "Preeclampsia is a pregnancy-related pathological condition triggered by an abnormal placentation which produces endothelial dysfunction (ED)." | ( Hinojosa-Cruz, JC; López-Alarcón, M; Montalvo-Velarde, I; Puellotamara, E; Vital-Reyes, VS, 2015) |
| "Preeclampsia is the 2nd leading cause of maternal mortality in the United States." | ( Chappelle, J; Crnosija, N; So, J; Young, E, 2016) |
| "Preeclampsia is a maternal hypertensive disorder with uncertain etiology and a leading cause of maternal and fetal mortality worldwide, causing nearly 40% of premature births delivered before 35 weeks of gestation." | ( Dobierzewska, A; España-Perrot, PP; Figueroa-Diesel, H; González, MI; Guzmán-Rojas, AM; Illanes, SE; Irarrazabal, CE; Monteiro, LJ; Palominos-Rivera, M; Perez-Sepulveda, A; Varas-Godoy, M; Venegas-Araneda, P, 2015) |
| "Preeclampsia is a potentially fatal pregnancy disorder affecting millions of women around the globe." | ( Boggess, K; Fry, RC; Grace, MR; Martin, E; Ray, PD; Smeester, L, 2015) |
| "Preeclampsia is a hypertensive disorder of pregnancy which is one of the leading causes of maternal and perinatal mortality and pre-term delivery, especially in low and middle income countries." | ( Ahmed, S; Akter, M; Anonna, SN; Haque, MM; Islam, MS; Karmakar, P; Moghal, MM; Sarwar, MS; Sattar, MA, 2016) |
| "Preeclampsia is associated with placental ischemia/hypoxia and secretion of soluble fms-like tyrosine kinase 1 and soluble endoglin into the maternal circulation." | ( Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Illanes, SE; Kaitu'u-Lino, TJ; Parry, LJ; Senadheera, S; Tong, S; Tuohey, L, 2016) |
| "Preeclampsia is the main complication of pregnancy in developing countries." | ( Alzate, A; Herrera-Medina, R; Pineda, LM, 2015) |
| "Preeclampsia is characterized by disturbed placentation, hypertension, proteinuria, and suppression of plasma renin, angiotensin II, and aldosterone." | ( Andersen, LB; Frederiksen-Møller, B; Hansen, MR; Jensen, BL; Jørgensen, JS; Krigslund, O; Vogel, LK, 2016) |
| "Preeclampsia is not associated with altered prostasin in placenta or plasma at term, but with increased prostasin in urine." | ( Andersen, LB; Frederiksen-Møller, B; Hansen, MR; Jensen, BL; Jørgensen, JS; Krigslund, O; Vogel, LK, 2016) |
| "Preeclampsia is a pregnancy-specific syndrome characterized by placental dysfunction and an angiogenic imbalance." | ( Baelde, HJ; Bloemenkamp, KW; Bruijn, JA; Turner, RJ, 2016) |
| "(3) Preeclampsia is associated with a low renal and/or sweating capacity, or in rare cases, with increased norepinephrine production due to maternal pheochromocytoma and fetal neuroblastoma." | ( Chen, NN; Li, D; Zhou, SS; Zhou, YM, 2016) |
| "Preeclampsia is mainly due to decreased excretion of norepinephrine and other vasoactive amines." | ( Chen, NN; Li, D; Zhou, SS; Zhou, YM, 2016) |
| "Preeclampsia is associated with an increased inflammatory response." | ( Bao, J; Brennecke, SP; Hu, B; Huang, Q; Liu, H; Yang, J, 2016) |
| "Preeclampsia is frequent in Kinshasa (Democratic Republic of Congo), especially during the dry season." | ( Buassa-Bu-Tsumbu, B; Elongi Moyene, JP; Haufroid, V; Nemery, B; Scheers, H; Spitz, B; Tandu-Umba, B; Verdonck, F, 2016) |
| "Preeclampsia is becoming an increasingly common diagnosis in the developed world and remains a high cause of maternal and fetal morbidity and mortality in the developing world." | ( Brima, W; Jim, B; Phipps, E; Prasanna, D, 2016) |
| "Preeclampsia is associated with the placental release of soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG)." | ( Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Kaitu'u-Lino, TJ; Tong, S, 2016) |
| "Preeclampsia is associated with an imbalance in vasoactive factors, including nitric oxide (NO), hydrogen sulfide (H2S), and renin-angiotensin system (RAS)." | ( Hsu, CN; Lee, CT; Lin, YJ; Tain, YL; Tsai, CC, 2016) |
| "Preeclampsia is a hypertensive disorder of pregnancy that remains a significant cause of maternal morbidity and mortality worldwide." | ( Kanellopoulou, T; Katsi, V; Makris, T; Nihoyannopoulos, P; Nomikou, E; Tousoulis, D, 2016) |
| "Preeclampsia is a hypertensive disorder of pregnancy in which patients develop profound sensitivity to vasopressors, such as angiotensin II, and is associated with substantial morbidity for the mother and fetus." | ( Burke, SD; Clark, CD; DuPont, JJ; Jaffe, IZ; Kang, PM; Karumanchi, SA; Khankin, EV; Lo, AS; McCurley, A; Moss, ME; Rajakumar, A; Seely, EW; Stillman, IE; Wang, A; Zhang, D; Zsengellér, ZK, 2016) |
| "Preeclampsia is a pregnancy-specific disorder characterised by an inappropriate maternal inflammatory response during pregnancy." | ( Chamley, L; Chen, Q; Shen, F; Tong, M; Wei, J; Yin, YX; Zhao, M, 2016) |
| "Preeclampsia is one of the most commonly encountered hypertensive disorders of pregnancy." | ( Abebe, F; Assefa, M; Assress, M; Endeshaw, M; Menber, L; Worku, S, 2016) |
| "Preeclampsia is an important pregnancy-specific multisystem disorder characterized by the onset of hypertension and proteinuria." | ( de Lucca, L; Gallarreta, FMP; Gonçalves, TL; Jantsch, LB; Kober, H; Neme, WS; Rodrigues, F, 2016) |
| "Risk factors for preeclampsia are well established, whereas, the triggers associated with timing of preeclampsia onset are not." | ( Ford, JB; Herbert, RD; Morris, J; Patterson, JA; Roberts, CL; Schemann, K, 2016) |
| "Preeclampsia is a severe pregnancy complication mostly due to inadequate vascular dilation and remodeling of spiral arteries." | ( Chen, R; Feng, L; Guo, X; Jia, J; Yu, J, 2016) |
| "Frequency of severe preeclampsia is lower in low Na/K group than medium or high Na/K groups (p=0." | ( Akkaş, E; Kara, Ö; Türkmen, GG; Uygur, D; Yılmaz, ZV; Yücel, A, 2017) |
| "Preeclampsia is a multisystem disorder that affects 3% to 5% of pregnant women and remains a significant source of short-term and long-term maternal and neonatal mortality and morbidity." | ( Costantine, MM; Marrs, CC, 2017) |
| "Preeclampsia is a hypertensive disorder of pregnancy, responsible for over 60 000 maternal deaths annually." | ( Brownfoot, F; Cannon, P; Hannan, NJ; Hastie, R; Kaitu'u-Lino, TJ; Tong, S, 2017) |
| "Preeclampsia is a specific disorder of human pregnancy that is associated with hyperuricemia and higher levels of pro-inflammatory cytokines." | ( Bannwart-Castro, CF; Borges, VT; Giorgi, VS; Peraçoli, JC; Peraçoli, MT; Romão-Veiga, M; Sartori, MS; Witkin, SS, 2016) |
| "Preeclampsia is a prevalent and enigmatic disease, in part characterized by poor remodeling of the spiral arteries." | ( Cantonwine, DE; Ferguson, KK; McElrath, TF; Meeker, JD; Mukherjee, B, 2017) |
| "Preeclampsia is a cause of maternal and perinatal morbidity and mortality affecting 3-5% of pregnancies." | ( Chiarello, DI; Farías, M; Gutiérrez, J; Leiva, A; Mate, A; Pardo, F; Salsoso, R; Sobrevia, L; Toledo, F; Vázquez, CM, 2017) |
| "Preeclampsia is known to be of placental origin and a major cause of maternal morbidity and mortality worldwide." | ( Joshi, SR; Nandi, AA; Wadhwani, NS, 2017) |
| "Preeclampsia is characterised by systemic endothelial cell dysfunction thought to be triggered by toxic/dangerous factors from the placenta, including placental extracellular vesicles (EVs)." | ( Chamley, LW; Chen, Q; Stone, PR; Tong, M; Wise, MR; Xiao, F; Xiao, X; Zhao, M, 2017) |
| "If the incidence of preeclampsia is lower than 51." | ( Chicaíza-Becerra, LA; García-Molina, M; Gómez-Sánchez, PI; Oviedo-Ariza, SP; Rincón-Rodríguez, CJ; Rubio-Romero, JA; Urrego-Novoa, JR, 2016) |
| "Preeclampsia is a pregnancy complication which manifests as new-onset hypertension, proteinuria, and a spectrum of other symptoms." | ( Arany, M; Cockrell, K; Gadepalli, RSV; George, EM; Granger, JP; Rimoldi, JM; Stec, DE, 2017) |
| "Preeclampsia is a hypertensive disorder in pregnancy where a patients' blood pressure and warning signs of worsening disease need to be closely monitored during pregnancy and the postpartum period." | ( Eswaran, H; Gauss, CH; Lowery, CL; Lynch, CE; Ounpraseuth, ST; Payakachat, N; Rhoads, SJ; Serrano, CI, 2017) |
| "Preeclampsia is a disease of pregnancy associated with placental oxidative stress, inflammation and elevated release of anti-angiogenic factors sFlt-1 and soluble endoglin." | ( Beard, S; Brownfoot, FC; Cannon, P; Deo, M; Hannan, NJ; Kaitu'u-Lino, TJ; Nguyen, TV; Palmer, KR; Tong, S, 2017) |
| "Preeclampsia is a multi-systemic, multi-organ dysfunction associated with increased maternal and perinatal complications." | ( Keepanasseril, A; Manikandan, K; Maurya, DK; Soundara Raghavan, S; Suriya, JY; Veena, P, 2017) |
| "Preeclampsia is one of the main contributers to maternal and fetal morbidity and mortality during pregnancy." | ( Brodowski, L; Burlakov, J; Hass, S; von Kaisenberg, C; von Versen-Höynck, F, 2017) |
| "Preeclampsia is a complication affecting pregnant women worldwide, which leads to maternal and fetal morbidity and mortality." | ( Gong, W; Man, Q; Wan, J; Yuan, Q; Zhang, X, 2017) |
| "Preterm preeclampsia is an important cause of maternal and perinatal death and complications." | ( Akolekar, R; Cicero, S; de Paco Matallana, C; Gizurarson, S; Janga, D; Jani, JC; Maclagan, K; Meiri, H; Molina, FS; Nicolaides, KH; O'Gorman, N; Papaioannou, G; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Singh, M; Syngelaki, A; Tenenbaum-Gavish, K; Wright, D, 2017) |
| "Preeclampsia is characterized by blood pressure greater than 140/90 mmHg in the second half of pregnancy." | ( Amaral, LM; LaMarca, B; Owens, M; Wallace, K, 2017) |
| "Preeclampsia is a pregnancy‑specific disorder, which is a leading cause of maternal and perinatal mortality and morbidity." | ( Baker, PN; Chen, X; Feng, X; Mao, X; Tong, C; Xia, Y; Zhang, H; Zhao, D; Zhou, L, 2017) |
| "Preeclampsia is a severe pregnancy-specific syndrome defined as newly onset hypertension and proteinuria." | ( Bai, Y; Guo, X; Li, YX; Liu, M; Peng, C; Sha, J; Wang, H; Wang, YL; Zhang, L, 2018) |
| "Preeclampsia is thought to originate during placentation, with incomplete remodelling and perfusion of the spiral arteries leading to reduced placental vascular capacity." | ( Avery, CL; Bauer, AE; Engel, SM; Harmon, QE; Klungsøyr, K; Luo, J; Magnus, P; Manuck, TA; McGinnis, R; Morgan, L; Olshan, AF; Shi, M; Trogstad, L; Weinberg, CR; Williams, N; Wu, MC; Yang, J, 2018) |
| "The exact cause of preeclampsia is unknown." | ( Chamley, LW; Chen, Q; Groom, K; Hickey, A; Li, Y; Stone, PR; Xu, L; Zhao, M, 2017) |
| "Preeclampsia is a serious complication of pregnancy characterized by the development of vasospasm, hypertension and often associated with proteinuria after the 20th week of gestation." | ( Joiakim, A; Kim, H; Park, JA; Putt, DA; Santos, JM; Taylor, RN, 2017) |
| "Preeclampsia is a severe complication of pregnancy associated with maternal and fetal morbidity and mortality." | ( Lee, DK; Nevo, O; Sengupta, A, 2018) |
| "Preeclampsia is a pregnancy-specific condition manifested by new-onset maternal hypertension with systemic inflammation, including increased innate immune system complement activation." | ( Gilbert, JS; Laule, CF; Odean, EJ; Regal, JF; Wilcox, JA; Wing, CR, 2017) |
| "Maternal TAS in preeclampsia is useful in predicting poor motor development at one year corrected age." | ( Adhisivam, B; Bharadwaj, SK; Bobby, Z; Habeebullah, S; Vickneswaran, V; Vishnu Bhat, B, 2018) |
| "Preeclampsia is a common medical complication in pregnancy." | ( Kitporntheranunt, M; Kreepala, C; Rungsrithananon, W; Sangwipasnapaporn, W; Wattanavaekin, K, 2018) |
| "Preeclampsia is a multi-system disorder in pregnancy which has no effective treatment." | ( Cui, L; Cui, M; Hai, H; He, J; Jiang, J; Li, Y; Liu, X; Liu, Z; Shu, C; Tang, JJ; Tong, W; Wei, C; Ye, F; Zhang, DY, 2018) |
| "Preeclampsia is associated with the presence of pathogenic angiotensin-receptor-activating autoantibodies." | ( Chen, Y; Huang, Y; Jiang, W; Wang, F; Wu, J; Xu, H; Yan, Y; Ye, D; Yu, D; Zhang, K; Zhang, Q; Zhao, Y, 2018) |
| "Preeclampsia is a hypertensive, gestational disease, which is still the leading cause of pregnancy related morbidity and mortality." | ( Baier, F; Beckmann, MW; Betzler, A; Fahlbusch, FB; Hartner, A; Huebner, H; Kehl, S; Knoerr, B; Ruebner, M; Strick, R; Wachter, DL, 2018) |
| "Preeclampsia is a hypertensive disorder specific to pregnancy that remains a significant cause of maternal and neonatal morbidity and mortality." | ( Fantasia, HC, 2018) |
| "Preeclampsia is a multifactorial and pathogenic pathway syndrome." | ( Huai, J; Wang, GJ; Yang, Z; Yi, YH, 2018) |
| "Preeclampsia is a condition that might severely impact the health of mothers and their newborns." | ( Alhag, SM; Elgari, MM; Khabour, OF, 2019) |
| "Preeclampsia is a major pregnancy complication with adverse short- and long-term implications for both the mother and baby." | ( de Alvarado, M; de Paco Matallana, C; Jani, JC; Machuca, M; Mastrodima, S; Molina, FS; Nicolaides, KH; Papaioannou, G; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Shearing, S; Syngelaki, A; Tan, MY; Wright, D, 2018) |
| "Preeclampsia is one of the most serious complications of pregnancy." | ( Beard, S; Binder, NK; Hannan, NJ; Kaitu'u-Lino, TJ; Nguyen, TV; Tong, S, 2018) |
| "Preeclampsia is a major cause of maternal and fetal morbidity and mortality worldwide." | ( Antonio Barbieri, M; Bettiol, H; Caldeira-Dias, M; Cardoso, VC; Carvalho, RF; Cavalli, RC; Deffune, E; Freire, PP; Luizon, MR; Sandrim, VC; Tanus-Santos, JE, 2018) |
| "Preeclampsia is reported in pregnant women around the world and often causes maternal/fetal mortality and morbidity." | ( He, Z; Wang, D; Xiao, S; Zhang, M, 2018) |
| "Preeclampsia is a heterogeneous pregnancy-specific syndrome associated with abnormal trophoblast invasion and endothelial dysfunction." | ( Chiarello, DI; Coronado, P; Gutiérrez, J; Marín, R; Proverbio, F; Salsoso, R; Sobrevia, L; Toledo, F, 2018) |
| "Preeclampsia is a severe pregnancy-related disorder, and patients usually present with high circulating inflammatory factor levels and excessive activation of the nuclear factor-κB (NF-κB) pathway." | ( Li, G; Lin, L; Ma, L; Wang, YL; Yang, H, 2018) |
| "Preeclampsia is one of the most serious pregnancy complications." | ( Gao, H; He, Q; Li, M; Liu, Y; Mei, L; Qiu, Y; Tang, J; Tang, L; Wang, X; Xu, W; Yang, M; Yu, Q; Zhang, Z, 2018) |
| "Preeclampsia is a significant contributor to maternal and neonatal morbidity and mortality." | ( Bulloch, RE; Jordan, VMB; Lovell, AL; McCowan, LME; Thompson, JMD; Wall, CR, 2018) |
| "Preeclampsia is one of the most frequent and difficult illnesses in pregnancy, which jeopardizes both mother and fetus." | ( Bai, C; Ding, L; Liu, Y, 2018) |
| "Preeclampsia is associated with increased risk for later cardiovascular disease." | ( Agassi-Zaitler, M; Benchetrit, S; Biron-Shental, T; Einbinder, Y; Khatib, S; Ohana, M; Tzadikevitch-Geffen, K; Vaya, J; Zitman-Gal, T, 2018) |
| "Women at risk of preeclampsia are defined based on the presence of one or more high-risk factors (history of preeclampsia, multifetal gestation, renal disease, autoimmune disease, type 1 or type 2 diabetes, and chronic hypertension) or more than one of several moderate-risk factors (first pregnancy, maternal age of 35 years or older, a body mass index greater than 30, family history of preeclampsia, sociodemographic characteristics, and personal history factors)." | ( , 2018) |
| "Women at risk of preeclampsia are defined based on the presence of one or more high-risk factors (history of preeclampsia, multifetal gestation, renal disease, autoimmune disease, type 1 or type 2 diabetes, and chronic hypertension) or more than one of several moderate-risk factors (first pregnancy, maternal age of 35 years or older, a body mass index greater than 30, family history of preeclampsia, sociodemographic characteristics, and personal history factors)." | ( , 2018) |
| "Preeclampsia is an inflammatory disease and has connection with increased pro-inflammatory cytokines." | ( Liu, F; Lu, X; Sun, J; Tang, D; Zhang, H, 2018) |
| "Preeclampsia is a hypertensive disorder of pregnancy known to increase the risk of cardiovascular disease in mothers and offspring." | ( Heffernan, S; Hennessy, A; Lind, JM; Makris, A; Pears, S; Sunderland, N; Xu, B; Yeung, KR, 2018) |
| "Preeclampsia is the most common hypertensive disorder of pregnancy, often responsible for severe maternal and fetal complications, which can lead to early pregnancy termination and death." | ( da Costa, BEP; do Amaral, RR; Larré, AB; Paludo, N; Pasin, DM; Poli-de-Figueiredo, CE; Sontag, F, 2018) |
| "Preeclampsia is a major health problem in human pregnancy, severely complicating 5-8% of all pregnancies." | ( Al-Nasiry, S; Bast, A; Janssen, GMJ; Schiffers, PMH; Spaanderman, ME; Vangrieken, P; Weseler, AR, 2018) |
| "Preeclampsia is a disorder characterized by high blood pressure and often proteinuria during pregnancy." | ( Ahishali, B; Arican, N; Elmas, I; Gürses, C; Kaya, M; Kucuk, M; Orhan, N; Ugur Yilmaz, C, 2018) |
| "Preeclampsia is a common obstetrical complication, hallmarked by new-onset hypertension." | ( Chapman, H; Eddy, AC; George, EM, 2019) |
| "Preeclampsia is characterized by an increased sensitivity to angiotensin II (Ang II)." | ( Berumen-Lechuga, MG; Isordia-Salas, I; Leaños-Miranda, A; Méndez-Aguilar, F; Molina-Pérez, CJ; Ramírez-Valenzuela, KL; Sillas-Pardo, LJ; Uraga-Camacho, NC, 2018) |
| "Preeclampsia is also associated with elevated placental androgen receptor (AR) gene expression." | ( Abbott, DH; Gordon, GH; Kumar, S; Mishra, JS, 2018) |
| "Preeclampsia is a hypertensive disorder of pregnancy and the clinical manifestation of severe endothelial dysfunction associated with maternal and foetal morbidity and mortality." | ( Hertig, A; Lecarpentier, E; Simon-Tillaux, N; Tsatsaris, V, 2019) |
| "Preeclampsia is a devastating pregnancy disorder." | ( Callaway, L; Cuffe, JSM; Dekker Nitert, M; Holland, OJ; Kwan Cheung, KA; Perkins, AV; Radenkovic, F, 2018) |
| "Preeclampsia is the most frequent pregnancy-related complication worldwide with no cure." | ( AbdAlla, S; Bayoumy, KM; Fu, X; Langer, A; Pohl, A; Quitterer, U, 2019) |
| "Preeclampsia is associated with intermittent placental hypoxia, inflammation and the release of antiangiogenic factors, namely sFLT-1 and sEng." | ( Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Kaitu'u-Lino, TJ; Nguyen, V; Tong, S; Ye, L, 2018) |
| "Preeclampsia is a hypertensive disorder in pregnant women, which can be the leading cause of maternal and neonatal death or premature birth." | ( Taravati, A; Tohidi, F, 2018) |
| "BACKGROUND Preeclampsia is a multifaceted pregnancy-related disorder affecting women and fetuses." | ( Adefolaju, FO; Ekun, OA; Lawal, RA; Ogidi, NO; Ogunmuyiwa, OA; Oremosu, AI; Oshundun, MF; Umewune, MC, 2018) |
| "Preeclampsia is one of the leading causes of maternal and neonatal mortality and morbidity worldwide." | ( Baba, T; Chigusa, Y; Horie, A; Kawamura, Y; Kawasaki, K; Kondoh, E; Konishi, I; Mandai, M; Matsumura, N; Mogami, H; Takeda, S, 2019) |
| "Preeclampsia is a pregnancy-related hypertensive disorder accounting for 14% of global maternal deaths annually." | ( Bayer, CL; Escott, ME; Intapad, S; Lawrence, DJ; Lindsey, SH; Myers, L, 2019) |
| "Preeclampsia is one of the most serious complications during pregnancy, defined as development of hypertension during late pregnancy affecting other organ systems (proteinuria, thrombocytopenia, renal insufficiency, liver involvement, cerebral symptoms or pulmonary edema)." | ( Choi, MH; Jun, JK; Kim, BJ; Kim, SM; Lee, SM; Lim, BY; Moon, JY; Norwitz, ER; Park, CW; Park, JS, 2019) |
| "Preeclampsia is a pregnancy-specific disorder that is a major cause of maternal and fetal morbidity and mortality with a prevalence of 6-8% of pregnancies." | ( Huang, X; Jia, L; Jia, Y; Jin, LP; Wang, K; Xie, D; Xu, XH; Zheng, Q; Zhou, Q; Zhou, X, 2019) |
| "Preeclampsia is a major complication of pregnancy with no medical treatment." | ( Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Kaitu'u-Lino, TJ; Nguyen, V; Parry, LJ; Senadheera, S; Tong, S; Tuohey, L, 2019) |
| "Preeclampsia is the cause of significant maternal and fetal mortality and morbidity." | ( Gupta, SK; Jee, B; Malik, A, 2019) |
| "Preeclampsia is a common pregnancy complication." | ( Barak, T; Burg, A; Cervil, S; Hamou, B; Saphier, O; Silberstein, T, 2019) |
| "Preeclampsia is a syndrome characterised by vascular dysfunction, impaired angiogenesis, and hypertension during pregnancy." | ( Chiarello, DI; Gómez, I; Gutiérrez, JA; Guzmán-Gutiérrez, E; Klein, AD; Salsoso, R; Sobrevia, L; Toledo, F, 2020) |
| "Preeclampsia is a multisystem disorder associated with pregnancy and is a common cause of perinatal morbidity." | ( Cho, NJ; Kim, YS; Lee, EY; Ryu, A, 2019) |
| "Preeclampsia is a pregnancy complication associated with elevated placental secretion of anti-angiogenic factors, maternal endothelial dysfunction and end-organ injury." | ( Alwis, N; Cannon, P; Hannan, NJ; Hastie, R; Kaitu'u-Lino, T; MacDonald, TM; Nguyen, TV; Pritchard, N; Tong, S; Walker, SP; Whigham, CA, 2019) |
| "Preeclampsia is one of the most frequent complication of pregnancy which manifested by hypertension during pregnancy for the first time after 20th weeks of gestation with proteinuria." | ( Alam, MT; Begum, S; Chakraborty, PK; Hoque, MR; Rahman, MM; Sarkar, S; Tuli, JZ, 2019) |
| "Preeclampsia is a serious, pregnancy-specific, multi-organ disease process of compound aetiology." | ( Dymara-Konopka, W; Laskowska, M, 2019) |
| "Preeclampsia is a pregnancy-associated disorder with an immune basis and is linked to atopic disorders in offspring." | ( Benzie, R; Chidgey, A; Collier, F; Dahlstrom, JE; Daly, NL; Eviston, D; Hsu, P; Hu, M; Joung, S; Macia, L; Mackay, CR; Mariño, E; Nanan, R; O'Hely, M; Peek, M; Ponsonby, AL; Quinton, A; Richards, JL; Santner-Nanan, B; Tang, MLK; Vuillermin, P; Wilson, D; Wong, K; Yap, YA, 2019) |
| "Preeclampsia is associated with reduction of utero-placental blood flow, which is reflected in high blood pressure and proteinuria during the second half of pregnancy." | ( Chowdhury, AA; Keya, SL; Khanam, NN; Ripon, R; Sharmin, A; Tasnim, T, 2019) |
| "Preeclampsia is a prevalent pregnancy complication characterized by new-onset maternal hypertension and inflammation, with placental ischemia as the initiating event." | ( Fleming, SD; Gilbert, JS; Hamm, CM; Laule, CF; Odean, EJ; Regal, JF; Root, KM; Towner, KJ; Wing, CR, 2019) |
| "; Early-onset preeclampsia is a rare pregnancy-specific disorder associated with significantly increased maternal and fetal morbidity and mortality." | ( Áinle, FN; Allen, S; Donnelly, JC; Egan, K; Galligan, M; Haire, G; Hunt, B; Kevane, B; Maguire, P; McCallion, N; McKinnon, T; Monteith, C; O'Connor, H; Parmar, K; Szklanna, PB, 2019) |
| "Preeclampsia is of two types, i." | ( Dalvi, S; Joshi, S; Kale, A; Kasture, V; Sundrani, D; Swamy, M, 2019) |
| "Background Preeclampsia is a leading contributor to maternal and perinatal morbidity and mortality." | ( Guallar, E; Hong, X; Liu, T; Mueller, NT; Wang, G; Wang, X; Zhang, M, 2019) |
| "Preeclampsia is a major cause of maternal, fetal and neonatal morbidity and mortality, particularly in developing countries." | ( Chandak, GR; Chandhiok, N; Fall, CHD; Gupte, SA; Joshi, PC; Joshi, SR; Kinare, AS; Lalwani, SK; Mani, NS; Mehendale, SS; Sundrani, DP; Tipnis, MM; Wadhwani, NS; Wagh, GN, 2019) |
| "Preeclampsia is characterized by an imbalance in angiogenic factors, including sEng (soluble endoglin)." | ( Isordia-Salas, I; Jiménez-Trejo, LM; Leaños-Miranda, A; Navarro-Romero, CS; Ramírez-Valenzuela, KL; Sillas-Pardo, LJ, 2019) |
| "Preeclampsia is a pregnancy-specific hypertensive disorder characterized by impaired angiogenesis." | ( Butler Tobah, YS; Chebib, FT; Cubro, H; Garovic, VD; Grande, JP; Jordan, KL; Kirkland, JL; Lerman, LO; Milic, NM; Suvakov, S; Tchkonia, T; Weissgerber, TL; White, WM; Woollard, JR; Xu, M; Zhu, XY, 2019) |
| "Preeclampsia is a common cause of acute kidney injury (AKI) in low- and middle-income countries, but AKI incidence in preeclampsia, its risk factors, and renal outcomes are unknown." | ( Bramham, K; Chappell, LC; Conti-Ramsden, FI; De Greeff, A; Hall, DR; Nathan, HL; Seed, PT; Shennan, AH, 2019) |
| "Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality." | ( Langston-Cox, AG; Marshall, SA; Palmer, KR; Wallace, EM, 2019) |
| "Preeclampsia is a hypertensive disorder of pregnancy characterized by systemic perturbations of nitric oxide function, reflective of generalized endothelial dysfunction." | ( Maeda, KJ; Ryan, MJ; Sasser, J; Younes, ST, 2020) |
| "Preeclampsia is a pregnancy complication, associated with an increased risk of maternal and neonatal morbidity and mortality." | ( Joshi, SR; Nandi, A; Randhir, K; Wadhwani, N; Wagh, G, 2020) |
| "Preeclampsia is associated with increased cardiovascular long-term risk; however, the underlying functional and structural mechanisms are unknown." | ( Birukov, A; Dechend, R; Geisberger, S; Golic, M; Haase, N; Herse, F; Heuser, A; Kräker, K; Müller, DN; O'Driscoll, JM; Patey, O; Schütte, T; Thilaganathan, B; Verlohren, S, 2020) |
| "Preeclampsia is responsible for significant maternal and neonatal morbidity and is associated with a substantial economic burden." | ( Afshar, Y; Bromley, B; Caughey, AB; Chescheir, N; Copel, JA; Grechukhina, O; Grobman, W; Han, CS; Hobbins, JC; Mallampati, D; Nicolaides, K; Pettker, C; Platt, LD; Saade, G; Sibai, B; Simhan, H; Sonek, J; Werner, E, 2020) |
| "Considering preeclampsia is a syndrome solely occurring among pregnant women, this review focuses on NO signaling in clinical studies, with supplementary evidence from animal studies added when necessary." | ( Gemmel, M; Powers, RW; Sutton, EF, 2020) |
| "Preeclampsia is a multisystemic disorder of pregnancy that causes perinatal morbidity and mortality." | ( Dublán-García, O; Gómez-Oliván, LM; Islas-Flores, H; San Juan-Reyes, S, 2020) |
| "Preeclampsia is a serious hypertensive disorder of pregnancy, which is only cured with delivery of the placenta, thereby commonly necessitating preterm birth of the fetus." | ( Baczyk, D; Kingdom, JC; Wat, JM, 2020) |
| "Preeclampsia is an inflammatory disease which can induce oxidative stress in placenta." | ( Huang, J; Kong, H; Su, Y; Wang, F; Xin, H; Zheng, L, 2020) |
| "Preeclampsia is considered a specific disease of pregnancy, but recent theories suggest that women suffering from the condition have greater propensity to develop atherosclerosis, heart disease, and stroke over the years." | ( Diniz, AD; Diniz, ALD; Paes, MMBM, 2020) |
| "Preeclampsia is defined as hypertension (systolic pressure ≥140 mmHg or diastolic pressure ≥90 mmHg) after week 20 of gestation with one or more of the following symptoms: proteinuria, organ dysfunction (including renal, hepatologic, hematologic or neurological complications) and in case of stagnation of fetal development." | ( Dzihic, E; Iglica, A; Mahmutbegovic, E; Medjedovic, E; Muftic, A; Rama, A; Suljevic, A, 2019) |
| "Preeclampsia is the major cause of maternal morbidity and mortality in developing countries." | ( Alves, JGB; de Araújo, CAL; de Gusmão, IMB; de Sousa Oliveira, L; Guimarães, A; Ribeiro, M, 2020) |
| "Preeclampsia is a multisystem disorder of high prevalence in pregnant women characterized by the onset of high blood pressure and associated with increased levels of sEng." | ( Bartha, JL; Bernabeu, C; Casal, JI; Gallardo-Vara, E; Gamella-Pozuelo, L; Garcia-Palmero, I; López-Novoa, JM; Perez-Roque, L; Pericacho, M, 2020) |
| "Preeclampsia is characterized by the emergence of hypertension and proteinuria after 20 weeks of pregnancy, and it threatens both maternal and fetal lives if it proceeds unabated." | ( Fujii, T; Iriyama, T; Kumasawa, K; Nagamatsu, T; Osuga, Y, 2020) |
| "Preeclampsia is an obstetric disorder that affects 3-8% of pregnant women and remains a leading cause of short- and long-term neonatal and maternal morbidity and mortality." | ( Costantine, MM; Ma'ayeh, M, 2020) |
| "Preeclampsia is a devastating hypertensive disorder of pregnancy with unknown mechanism." | ( Cui, Y; Gong, L; Jing, T; Li, X; Lu, H; Ma, D; Tang, Y; Wu, S; Xiao, X; Xu, H; Zhang, J; Zhao, H; Zhou, Q, 2020) |
| " Preeclampsia is a major cause of perinatal and maternal morbidity and mortality." | ( Caeiro, F; Francisco, C; Gomes, H; Lourenço, I; Ribeiro, J; Rocha, P, 2020) |
| "Preeclampsia is a multifactorial hypertensive disorder of pregnancy, with variable presentation in both maternal and fetal factors, such that no treatment or marker is currently universal to all cases." | ( Bainbridge, SA; Benton, SJ; Cox, BJ; Gaudet, J; Grynspan, D; Robineau-Charette, P; Vanderhyden, BC, 2020) |
| "Preeclampsia is a common medical condition during pregnancy and a major cause of maternal and prenatal mortality." | ( Chen, M; Daiber, A; Li, H; Man, AWC; Münzel, T; Reifenberg, G; Wu, Z; Xia, N; Zhou, Y, 2020) |
| "Objectives Preeclampsia is a hypertensive disorder associated with pregnancy and is the leading cause of both maternal and neonatal morbidity and mortality." | ( Kazemirad, N; Kazemirad, Y; Lorzadeh, N, 2020) |
| "Preeclampsia is defined as hypertension arising after 20 weeks of gestational age with proteinuria or other signs of end-organ damage and is an important cause of maternal and perinatal morbidity and mortality, particularly when of early onset." | ( Nicolaides, KH; Poon, LC; Rolnik, DL, 2022) |
| "Preeclampsia is a severe disease of late pregnancy." | ( Avdeeva, E; Avdeeva, N; Beskhmelnitsyna, E; Bushueva, O; Denisyuk, T; Golubev, I; Gudyrev, O; Gureev, V; Korokin, M; Korokina, L; Lazareva, G; Peresypkina, A; Pobeda, A; Pokrovskaia, T; Pokrovskii, M; Soldatov, V; Zatolokina, M, 2020) |
| "Preeclampsia is a complex disease affecting 2-8% of pregnancies worldwide." | ( Beard, S; Binder, NK; Brownfoot, F; de Alwis, N; Hannan, NJ; Kaitu'u-Lino, TJ; Tong, S, 2020) |
| "Preeclampsia is a devastating medical complication of pregnancy that can lead to significant maternal and fetal morbidity and mortality." | ( Burke, SD; Karumanchi, SA; Rana, S, 2022) |
| "Preeclampsia is a hypertensive and inflammatory pregnancy disorder associated with cholesterol accumulation and inflammation at the maternal-fetal interface." | ( Aune, MH; Bjørge, L; Collett, K; Elschot, M; Gierman, LM; Iversen, AC; Mundal, SB; Rakner, JJ; Silva, GB; Sporsheim, B; Stødle, GS; Thaning, AJ; Thomsen, LCV, 2020) |
| "Preeclampsia is a pregnancy-specific hypertensive disorder characterized by proteinuria, and vascular injury in the second half of pregnancy." | ( Alexander, MP; Cubro, H; d'Uscio, LV; Garcia-Valencia, O; Garovic, VD; Grande, JP; Katusic, ZS; Kirkland, JL; Milic, NM; Nath, KA; Nath, MC; Parashuram, S; Quinton, RA; Sontag, F; Suvakov, S; Tchkonia, T; Weissgerber, TL; White, WM; Zhu, Y, 2021) |
| "Preeclampsia is a pregnancy-related multisystem disorder, frequently encountered pregnancy-related medical complications next to gestational diabetes mellitus." | ( Divyashree, S; Janhavi, P; Muthukumar, SP; Nirupama, R; Ravindra, PV, 2021) |
| "Preeclampsia is a severe pregnancy complication with high potential for adverse effects on maternal and fetal health during the perinatal period." | ( Kay, VR; Smith, GN; Wedel, N, 2021) |
| "Toxemia of pregnancy is a very dangerous disease for pregnant women." | ( Hsiao, HC; Huang, CY, 2020) |
| "Preeclampsia is a pregnancy-specific disorder, leading to maternal and infant morbidity and mortality." | ( Deshpande, JS; Joshi, SR; Madiwale, SD; Nandi, AA; Randhir, KN; Wadhwani, NS; Wagh, GN, 2021) |
| "Preeclampsia is a severe gestational hypertensive condition linked to child neuropsychiatric disorders, although underlying mechanisms are unclear." | ( Chilukuri, ASS; Grobe, JL; Gumusoglu, SB; Hing, BWQ; Kundu, S; Sandgren, JA; Santillan, DA; Santillan, MK; Scroggins, SM; Stevens, HE, 2021) |
| "Preeclampsia is the main cause of maternal and perinatal death, especially in developing countries." | ( Chen, Y; Tan, MH; Wu, SZ; Xu, HY; Zhang, MM; Zhu, QL, 2021) |
| "BACKGROUND Preeclampsia is a common complication of pregnancy and a major cause of morbidity and mortality of mothers and babies worldwide." | ( Ademi Ibishi, V; Bimbashi, A; Ibrahimi, L; Latifi Hoxha, S; Paçarada, M, 2021) |
| "Preeclampsia is associated with reduced nitric oxide (NO) bioavailability." | ( Cavalli, RC; Coeli-Lacchini, F; Lacchini, R; Luizon, MR; Pinto-Souza, CC; Sandrim, VC, 2021) |
| "Preeclampsia is one of the leading causes of maternal mortality-morbidity, and environmental factors act as the main driving force for the development of disease in genetically lean women." | ( Atakul, N; Atamer, Y; Demirel, M; Gul, AZ; Sarıkaya, U; Selek, S; Yıldız, T, 2022) |
| "Preeclampsia is a multifactorial disease of unknown etiology and is associated with oxidative stress." | ( Akhter, QS; Eza, LH; Lisa, SH; Munna, MA; Nessa, A, 2021) |
| "Preeclampsia is a severe gestational hypertensive disorder that occurs after 20 weeks' of gestation." | ( Kuo, PL; Su, MT; Tsai, HL; Tsai, PY; Wang, CY, 2021) |
| "Preeclampsia is a hypertensive disorder of pregnancy marked by an excessive inflammatory response." | ( Ali, MA; Issotina Zibrila, A; Kang, Y; Li, C; Liu, J; Liu, K; Osei, JA; Sun, Y; Wang, Z; Zafar, S, 2021) |
| "Preeclampsia is an anti-angiogenic and inflammatory state." | ( Schubert, CL; Yusuf, K, 2021) |
| "Preeclampsia is a well-known cause of maternal mortality and morbidity in Ethiopia." | ( Abdella, A; Ayele, W; Eke, AC; Gebreyohannes, RD, 2021) |
| "Preeclampsia is a severe hypertensive complication of pregnancy associated with significant maternal and fetal risk." | ( Gumusoglu, S; Santillan, D; Santillan, M; Scroggins, S; Vignato, J, 2021) |
| "Preeclampsia is a pregnancy-specific hypertensive disorder characterized by proteinuria and/or multisystem involvement." | ( Chebib, FT; Cubro, H; Cunningham, JM; Garovic, VD; Ghamrawi, R; Grande, JP; Kirkland, JL; Milic, NM; Milosavljevic, A; Nath, KA; Prata, LGPL; Suvakov, S; Tchkonia, T; Tobah, YSB; Tu, H; White, WM; Zhu, Y, 2021) |
| "Preeclampsia is associated with reduced pro-angiogenic Placental Growth Factor (PlGF) and increased levels of anti-angiogenic soluble FMS like tyrosine kinase-1 (sFlt-1)." | ( Brownfoot, F; Cannon, P; Hannan, NJ; Hastie, R; Kaitu'u-Lino, TJ; Kandel, M; Masci, J; Nguyen, TV; Pritchard, N; Tong, S; Whigham, CA, 2021) |
| "The occurrence of preeclampsia is significantly associated with severe COVID-19 infection requiring respiratory support." | ( Ande, A; Ezeanochie, M; Ndukwu, K; Osaikhuwuomwan, J; Uwagboe, C; Yusuf, S, 2021) |
| "Preeclampsia is one of the most serious health problems that affect pregnant persons." | ( Barry, MJ; Cabana, M; Caughey, AB; Davidson, KW; Davis, EM; Donahue, KE; Doubeni, CA; Kubik, M; Li, L; Mangione, CM; Ogedegbe, G; Pbert, L; Silverstein, M; Simon, MA; Stevermer, J; Tseng, CW; Wong, JB, 2021) |
| "Preeclampsia is a hypertensive disorder of pregnancy that poses serious maternal and infant health risks." | ( Henderson, JT; Redmond, N; Senger, CA; Thomas, RG; Vesco, KK, 2021) |
| "Preeclampsia is a leading preventable cause of maternal morbidity and mortality." | ( Bernard, M; Davis, AL; Hayani, L; Krishnamurti, T; Rodriguez, S; Simhan, HN, 2021) |
| "Preeclampsia is a multi-organ system disorder of pregnancy and is responsible for a significant rate of maternal morbidity and mortality worldwide." | ( Ali, N; Barman, Z; Das Trisha, A; Hafsa, JM; Hasan, M; Miah, R; Mou, AD, 2021) |
| "Preeclampsia is a pregnancy disorder characterized with abnormal placental angiogenesis." | ( Joshi, S; Nema, J; Randhir, K; Sundrani, D; Wadhwani, N, 2021) |
| "Preeclampsia is a complication during pregnancy characterised by new-onset hypertension and proteinuria that develops after 20 weeks of gestation." | ( Enis, RN; Fitri, AD; Harahap, AH; Harahap, H; Herlambang, H; Kusdiyah, E; Maharani, C; Puspasari, A; Syamsunarno, MRAA; Tarawifa, S, 2022) |
| "Preeclampsia is a multisystem hypertensive disorder of pregnancy that remains one of the leading causes of maternal and perinatal morbidity and mortality worldwide." | ( Barber, C; Hannan, NJ; Marshall, SA; Wallace, EM; Yap, Y, 2022) |
| "Preeclampsia is a leading cause of maternal mortality and morbidity in South Africa." | ( Businge, CB; Kengne, AP; Longo-Mbenza, B, 2022) |
| "Preeclampsia is a severe complication of pregnancy characterised by variable degrees of placental malperfusion." | ( Chu, Y; Gu, W; Liu, L; Wang, R; Xu, R, 2022) |
| "Preeclampsia is the main cause of maternal and perinatal death." | ( Chen, Y; Ou, QX; Tan, MH; Wu, SZ; Xu, HY; Zhang, MM; Zhu, QL, 2022) |
| "Preeclampsia is a disorder of pregnancy with accompanying high disease and economic burdens in the United States." | ( Garrett, MR; Johnson, AC; Sasser, JM; Turbeville, HR, 2020) |
| "As women with preeclampsia are at risk for hyponatremia, serum sodium levels should be monitored, especially in those with severe features." | ( Amsalem, H; Levit, L; Porat, S; Remer, C, 2022) |
| "Preeclampsia is a disorder of hypertension and proteinuria accompanied by abnormal inflammatory responses." | ( Chen, D; Ding, J; Liu, A; Yang, S, 2023) |
| "Preeclampsia is a hypertensive disease unique to pregnancy and has a significant impact on maternal and neonatal morbidity and mortality." | ( Olson, DN; Ranzini, AC; Russell, T, 2022) |
| "Preeclampsia is characterized by hypertension and proteinuria, which is associated with kidney injury." | ( Huang, S; Lu, Y; Sun, S; Tian, F, 2022) |
| "Preeclampsia is a multifactorial cardiovascular disorder of pregnancy." | ( Afrose, D; Chen, H; Hansbro, PM; Henessy, A; Liu, CC; McClements, L; Ranashinghe, A, 2022) |
| ""Classic" preeclampsia is a severe and quickly progressing condition with placental insufficiency and consequent fetal growth restriction and oligohydramnios." | ( Alemu Wami, G; Bódis, J; Farkas, B; Kovács, K; Tamás, P; Várnagy, Á, 2022) |
| "Preeclampsia is characterized by maternal hypertension and multi-organ injury." | ( Herbert, SL; Jeschke, U; Kuhn, C; Löb, S; Mahner, S; Mittelberger, J; Schmoeckel, E; Vattai, A; Wöckel, A, 2022) |
| "Preeclampsia is a devastating, multisystem disorder of pregnancy." | ( Beard, S; Binder, NK; Brownfoot, FC; de Alwis, N; Fato, BR; Hannan, NJ; Kadife, E; Kaitu'u-Lino, TJ; Keenan, E; Mangwiro, YTM; Pritchard, N, 2022) |
| "Preeclampsia is a life-threatening disorder of pregnancy unique to humans." | ( Dimitriadis, E; Menkhorst, E; Santos, L; St-Pierre, Y; Young, MJ; Zhang, JG; Zhou, W, 2022) |
| "Preeclampsia is associated with maternal and perinatal morbidity." | ( Cleary, EM; Costantine, MM; Kudrimoti, M; Patton, KG; Racchi, NW; Rood, KM, 2023) |
| "Preeclampsia is one of the most serious pregnancy complications." | ( Chen, HY; Chen, PF; Hsu, KF; Kang, L; Lin, SH; Lu, KM; Su, MT; Wang, XY; Yu, CH, 2022) |
| "Preeclampsia is a pregnancy-related condition that causes high blood pressure and proteinuria after 20 weeks of pregnancy." | ( Gao, N; Hong, H; Ma, Y; Peng, Y; Wan, A, 2022) |
| "Preeclampsia is a common disease during pregnancy that leads to fetal and maternal adverse events." | ( Chen, JY; Duan, CY; He, PC; Li, JQ; Liu, YH; Liu, YX; Lye, S; Tan, N; Wang, ZJ; Wei, YX; Xie, NJ; Xu, XJ; Zhang, YS, 2023) |
| "Preeclampsia is a multisystem illness that manifests in the third trimester of pregnancy after 20 weeks of gestation and is marked by proteinuria and hypertension (PE)." | ( Bhurer Yadav, B; Kaushik, P; Parasher, N; Singh, NK; Suri, A; Yadav, L, 2023) |
| "Preeclampsia is associated with an increased risk of adverse maternal and perinatal outcomes." | ( Aminuddin, NA; Mahdy, ZA; Sutan, R, 2022) |
| "Preeclampsia is a severe pregnancy-related hypertension disorder and refers to hypertension." | ( Guo, L; Hu, R; Liu, R; Xiao, S; Zhang, M, 2023) |
| "Preeclampsia is a pregnancy-specific disorder involving placental abnormalities." | ( Kramer, A; Narasimhan, P; Renecle, MD; Rumer, KK; Sehgal, S; Stefanski, AL; Winn, VD, 2022) |
| "Preeclampsia is a multi-system disease that can have severe, even fatal implications for the mother and fetus." | ( Beard, S; Binder, N; Brownfoot, FC; Hannan, N; Harper, A; Kadife, E, 2022) |
| "Preeclampsia is a multi-system disease that can have severe, even fatal implications for the mother and fetus." | ( Beard, S; Binder, N; Brownfoot, FC; Hannan, N; Harper, A; Kadife, E, 2022) |
| "Preeclampsia is a multi-system disease that can have severe, even fatal implications for the mother and fetus." | ( Beard, S; Binder, N; Brownfoot, FC; Hannan, N; Harper, A; Kadife, E, 2022) |
| "Preeclampsia is a hypertensive disorder of pregnancy and is due to abnormal placentation." | ( Ananth Karumanchi, S; Johnson, RJ; Kang, DH; Kojima, H; Kosugi, T; Kublickiene, K; Lanaspa, MA; Nakagawa, T; Rodriguez-Iturbe, B; Sanchez-Lozada, LG; Stenvinkel, P; Tolan, DR, 2023) |
| "Preeclampsia is known to be accompanied by dyslipidemia, albeit via unknown mechanisms." | ( Chen, Z; Danser, AHJ; Fan, X; Guo, H; Lu, X; Mulder, M; Ouyang, Z; Sun, F; Sun, Y; Tan, L; Verdonk, K; Wang, F; Yang, Q; Zhang, JV, 2023) |
| "Preeclampsia is a gestational disease characterized by two major pathological changes-shallow trophoblast invasion and impaired spiral artery remodeling." | ( Chu, N; Gu, WR; Li, DJ; Liu, HY; Liu, ZZ; Luo, SL; Pei, JN; Qiu, XM; Tang, Y; Wang, CJ; Wang, L; Yu, Y, 2023) |
| "It also shows that preeclampsia is associated with a disruption of the circadian rhythm of placental cells." | ( Bretelle, F; Coiffard, B; Desbriere, R; Diallo, AB; Donato, X; Katsogiannou, M; Mege, JL; Mezouar, S, 2023) |
| "Preeclampsia is a syndrome of high blood pressure (BP) with end organ damage in late pregnancy that is associated with high circulating soluble VEGF receptor (sFlt1 [soluble Fms-like tyrosine kinase 1])." | ( Biwer, LA; Camarda, ND; Carvajal, BV; Ibarrola, J; Jaffe, IZ; Karumanchi, SA; Lu, Q; Man, JJ; Seely, EW; Skurnik, G; Stepanian, A; Zsengeller, Z, 2023) |
| "Preeclampsia is a hypertensive disorder of pregnancy affecting up to 8% of pregnancies." | ( Costantine, MM; Eid, J; Rood, KM, 2023) |
| "Preeclampsia is associated with an increased lifelong risk of cardiovascular disease (CVD)." | ( Beard, S; Binder, NK; de Alwis, N; Fato, BR; Hannan, NJ; Kaitu'u-Lino, TJ; Nguyen, TV, 2023) |
| "Preeclampsia is a heterogeneous hypertensive disorder of pregnancy." | ( Cai, Z; Chang, CL; Hsu, SYT, 2023) |
| "Preeclampsia is a multisystemic disorder of pregnancy that affects 250,000 pregnant individuals in the United States and approximately 10 million worldwide per annum." | ( Barton, JR; Beck, S; Bernstein, IM; Buck, TE; Facco, FL; Forgues-Lackie, MA; Gernand, AD; Graves, CR; Hauspurg, A; Jeyabalan, A; King, TL; Manuck, TA; Myatt, L; Myers, JE; Powell, TM; Roberts, JM; Sutton, EF; Tinker, E; Tsigas, E, 2023) |
| "Preeclampsia is one of the most severe diseases among the hypertensive disorders of pregnancy (HDP) and the leading cause of maternal and fetal morbidity and mortality." | ( Agnoletti, D; Baracchi, A; Borghi, C; Degli Esposti, D; Montaguti, E; Piani, F; Scarduelli, S; Simonazzi, G; Tossetta, G; Verde, C, 2023) |
| "Preeclampsia is a dangerous complication that may leads to maternal and neonatal mortality." | ( Biswas, PS; Momo, FR; Nahar, K; Rahman, MM; Sarkar, S; Tuli, JZ, 2023) |
| "However, preeclampsia is most often associated with low HDL cholesterol, and the mechanisms behind this change are scarcely explored." | ( Antonić, T; Ardalić, D; Gojković, T; Ivanišević, J; Miković, Ž; Mitrović, M; Munjas, J; Spasojević-Kalimanovska, V; Stefanović, A; Vekić, J; Vladimirov, S; Zeljković, A, 2023) |
| "Preeclampsia is a maternal hypertension disorder associated with vascular dysfunction and fetal and placental growth restrictions." | ( da Silva, MLS; Dias-Junior, CA; Gomes, SEB; Martins, LZ; Molezini, L; Montenegro, MF; Rizzi, E; Rodrigues, SD, 2023) |
| "NO levels in preeclampsia are altered by VNTR intron 4 variants but not T786C variants." | ( Awuah, EO; Detoh, E; Fondjo, LA; Sakyi, SA; Senu, E, 2023) |
| "Preeclampsia is a hypertensive disorder of pregnancy characterized by chronic placental ischemia and suppression of proangiogenic proteins, causing oxidative stress, hypertension, and maternal systemic organ damage." | ( Drewlo, S; Grimaldi, B; Halari, CD; Kingdom, JC; Kohan-Ghadr, HR; Nandi, P, 2023) |
| "Preeclampsia is a placentally induced syndrome with diverse clinical presentation that currently has no cure." | ( Cao, Y; Huang, Y; Kong, X; Liu, X; Xu, J; Ye, L; Yuan, X; Zhang, X; Zhu, H, 2023) |
| "Early-onset preeclampsia is a potentially dangerous condition that can have a profound impact on the health of both the expectant mother and her unborn child." | ( He, W; Liu, G; Lu, J; Lv, L; Ren, C; Wang, Y; Wu, K; Yang, J; Yin, A; Zhang, Y; Zhao, X, 2023) |
| Excerpt | Reference |
|---|
| "Twelve patients with either severe preeclampsia (9) or eclampsia (3) were treated with intravenous diazoxide, 300-mg bolus, for the reduction of diastolic blood pressure (less than or equal 110 torr) after the usual and customary measures had been initiated to include parenteral MgSO4 and diazepam." | ( Arce, JJ; Bloom, RS; Clark, JH; Davidson, EC; Hamilton, CJ; Maidman, JE; Morris, JA, 1977) |
| "Nifedipine therapy for preeclampsia reduces maternal blood pressure but does not reduce number of days of maternal hospitalization or improve perinatal outcome." | ( Akl, S; Barton, JR; Mercer, BM; Sarinoglu, C; Sibai, BM, 1992) |
| "Also, patients with superimposed preeclampsia were treated with 40 mg/day oral nifedipine." | ( Boemi, M; De Tommaso, G; Fumelli, P; Garzetti, GG; Lucino, E; Romanini, C; Tranquilli, AL, 1992) |
| "The characteristics and treatment of preeclampsia and eclampsia are reviewed." | ( McCombs, J, 1992) |
| "Provided that preeclampsia comprises enhanced vascular actions of thromboxane A2, the present results support the established use of Mg++ in the treatment of this condition and suggest that calcium antagonists are of potential benefit." | ( Andersson, KE; Forman, A; Skajaa, K; Svane, D, 1990) |
| "Fifty-eight women with severe preeclampsia between 28-34 weeks' gestation qualified for a randomized controlled trial to establish whether elective delivery 48 hours after administration of betamethasone (aggressive-management group) or delivery later as indicated by maternal or fetal condition (expectant-management group) was more beneficial to maternal and fetal outcome." | ( Bam, R; Grove, D; Kotze, TJ; Odendaal, HJ; Pattinson, RC, 1990) |
| "Twenty patients with preeclampsia at a gestational age of 26 to 35 weeks were treated with oral nifedipine until delivery." | ( Akl, S; Fairlie, FM; Khoury, AD; Moretti, MM; Sibai, BM, 1990) |
| "Two women with preeclampsia treated with pindolol and propranolol became profoundly hypertensive when indomethacin was added because of premature contractions." | ( Freedman, S; Hod, M; Ovadia, Y; Schoenfeld, A, 1989) |
| "Treatment of preeclampsia with prostacyclin appears to be contraindicated because prostacyclin is a potent systemic vasodilator and the clinical outcome of preeclamptic women infused with prostacyclin has been poor." | ( Walsh, SW, 1989) |
| "There were significantly fewer cases of EPH gestosis in the magnesium group, and no serious side effects of treatment." | ( Bódis, L; Huhn, E; Kovács, L; Molnár, BG, 1988) |
| "Two women with preeclampsia treated unsuccessfully with alpha-methyldopa and magnesium sulfate became profoundly hypotensive when oral nifedipine was added." | ( Cámera, MI; Martinotti, A; Mayorga, LM; Vignolo, CA; Waisman, GD, 1988) |
| "Twenty-five women with preeclampsia who were scheduled to undergo cesarean section under general anesthesia were randomly assigned to either a labetalol pretreatment group (n = 15) or a control group (n = 10) who did not receive any antihypertensive therapy before the induction of anesthesia." | ( Chauhan, D; Mabie, WC; Ramanathan, J; Ruiz, AG; Sibai, BM, 1988) |
| "Despite preeclampsia our patient successfully completed her 6th pregnancy after treatment with corticosteroids, subcutaneous heparin, and low dose aspirin throughout the pregnancy." | ( Andreoli, J; Hakim, C; Maier, D; Parke, A; Randolph, J, 1986) |
| "Two hundred primigravid women with mild preeclampsia at 26-35 weeks' gestation were randomly allocated to treatment with hospitalization alone or combined with labetalol." | ( Gonzalez, AR; Mabie, WC; Moretti, M; Sibai, BM, 1987) |
| "3 patients with severe preeclampsia and intrauterine death in the third trimester also had successfully induced labor with extraovular administration of PGF2alpha." | ( Lauersen, NH; Wilson, KH, 1974) |
| "Ten women in pregnancy complicated by EPH gestosis were examined prior to and during treatment." | ( Kudelski, Z, 1982) |
| "Ten patients with preeclampsia were monitored with a Swan-Ganz thermodilution catheter before the start of treatment." | ( Groenendijk, R; Trimbos, JB; Wallenburg, HC, 1984) |
| "Experimental toxemia of pregnancy in late pregnancy in rabbits was induced by constriction of the aorta below the renal arteries, followed by estradiol administration." | ( Fukuda, O; Inao, H; Inoue, S; Ito, M; Lin, TH; Maeyama, M; Miyayama, Y; Nakayama, M, 1984) |
| "Pregnant women with either Type B EPH gestosis or gestosis alone were treated with low dose aspirin if thrombocytopenia were present (platelet counts below 75,000) or had platelet aggregation studies if their platelet counts were above 75,000." | ( Davis, RB; Goodlin, RC, 1983) |
| "22 patients with severe preeclampsia-eclampsia were treated in our Intensive Care Unit from 1972 to 1978." | ( Larsen, R; Radke, J; Turner, E, 1980) |
| "Forty-eight patients hospitalised for EPH gestosis were treated for hypertension, using one constant dosage of Dilatol tablets." | ( During, R; Mauck, I, 1980) |
| "To assess its efficacy in preventing preeclampsia, 60 mg/day aspirin or a matching placebo was administered to women in a double-blind fashion during the second and third trimesters." | ( Arheart, KL; Di Sessa, TG; Khoury, A; Moretti, ML; Pulliam, DA; Sibai, BM, 1994) |
| "Twenty mothers with moderate to severe preeclampsia were allocated to labetalol (Trandate) or hydralazine (Apresolin) antihypertensive treatment." | ( Faxelius, G; Hjertberg, R; Lagercrantz, H, 1993) |
| "Twenty patients with severe preeclampsia (diastolic blood pressure greater than 110 mmHg and 24-hour proteinuria greater than 500 mg) received intravenous (IV) nicardipine at 2, 4, or 6 mg/hour according to body weight (mean duration of treatment 5." | ( Carbonne, B; Jannet, D; Khelifati, Y; Milliez, J; Touboul, C, 1993) |
| "The patient had severe hyperthyroidism, preeclampsia, and congestive heart failure, which had not been treated until 36 weeks of gestational age." | ( Gotoh, R; Kagawa, T; Kaneko, M; Obayashi, Y; Terui, K; Yamada, H, 1996) |
| "Women with a diagnosis of mild preeclampsia at term were randomized to receive standard therapy during labor and for 12 hours post partum with either magnesium sulfate (n = 67) or a matching placebo solution (n = 68)." | ( Friedman, SA; Sibai, BM; Witlin, AG, 1997) |
| "Surveillance for preeclampsia was conducted by personnel unaware of treatment-group assignments, using standardized measurements of blood pressure and urinary protein excretion at uniformly scheduled prenatal visits, protocols for monitoring these measurements during the hospitalization for delivery, and reviews of medical records of unscheduled outpatient visits and all hospitalizations." | ( Bild, DE; Catalano, PM; Clemens, JD; Curet, LB; Cutler, JA; DerSimonian, R; Esterlitz, JR; Hauth, JC; Levine, RJ; Morris, CD; Raymond, EG; Sibai, BM, 1997) |
| "Management of preeclampsia is bed rest, aspirin administration, antihypertensive agents (beta-blockers, hydralazine, alpha-methyldopa) would be used for reduction of blood pressure." | ( Suzuki, H, 1997) |
| "One hundred forty-eight women with mild preeclampsia were randomly allocated to treatment with either bed rest alone (n=64) or in combination with nifedipine (n=84) at 26-36 weeks' gestation." | ( Barton, JR; Mercer, BM; Sibai, BM, 1997) |
| "Seventeen patients with preeclampsia were treated with a nitroglycerin patch, 10 mg per 24 hours, for three consecutive days between 28 and 36 weeks' gestation." | ( Cacciatore, B; Halmesmäki, E; Kaaja, R; Teramo, K; Ylikorkala, O, 1998) |
| "36 pregnant women with severe preeclampsia received fluid therapy and were randomly dividend in two groups of 18 patients each." | ( Jiménez Acevedo, AL; Rubio Guerra, AF; Salmerón Pérez, I; Sánchez García, AR; Vargas Ayala, G, 1998) |
| "New insights into the genetics of preeclampsia will contribute to the understanding of this disease and should ultimately lead to improved diagnosis and treatment." | ( Morgan, T; Ward, K, 1999) |
| "Among women with preeclampsia, 93 (60%) were treated with magnesium and 61 (40%) were not." | ( Croughan-Minihane, MS; Kilpatrick, SJ; Szal, SE, 1999) |
| "Although effective for treatment of preeclampsia/eclampsia, its use in the termination of preterm labor has recently been questioned." | ( Kaplan-Machlis, B; Swain, R, 1999) |
| "A causal treatment of preeclampsia is, with the exception of delivery, not possible up to now." | ( Bastert, G; Henschel, B; Schulz, M; Wacker, J; Werner, P, 1999) |
| "Etiology of preeclampsia is still largely unraveled and treatment is syndrome specific." | ( Leszczyńska-Gorzelak, B; Oleszczuk, JJ; Szymczyk, G, 2000) |
| "Melatonin could be useful in treating preeclampsia and possibly other clinical states involving excessive free radical production, such as intrauterine fetal growth retardation and fetal hypoxia." | ( Fukaya, T; Kaneda, C; Okatani, Y; Shinohara, K; Wakatsuki, A, 2001) |
| "Melatonin could be useful in treating preeclampsia and possibly other clinical states involving excess free radical production, such as fetal growth restriction and fetal hypoxia." | ( Fukaya, T; Okatani, Y; Shinohara, K; Taniguchi, K; Wakatsuki, A, 2001) |
| "Forty-two patients with toxemia of pregnancy (group 1) and 59 women at term without toxemia (group 2) with Bishop scores of < or = 6 were treated with 50 microg intravaginal misoprostol given four times at 4-h intervals." | ( Guvercinci, M; Sahin, HA; Sahin, HG; Surucu, R, 2001) |
| "The baseline risk of preeclampsia in women with abnormal uterine artery Doppler was 16%, and the number of women needed to be treated with aspirin to prevent one case of preeclampsia was 16 (95% CI 8, 316)." | ( Coomarasamy, A; Gee, H; Khan, KS; Papaioannou, S, 2001) |
| "Women with severe preeclampsia at at least 24 weeks' gestation were randomly assigned to receive either intrapartum epidural (n = 56) versus patient-controlled intravenous opioid analgesia (n = 60), and each was administered by a standardized protocol." | ( Chestnut, DH; Hauth, JC; Head, BB; Owen, J; Shih, G; Vincent, RD, 2002) |
| "We found that preeclampsia plasma (as compared to normal pregnancy plasma) (1) displays elevated endogenous ascorbate redox-cycling that is normalized by a Cu(II) chelator, cuprizone I, (2) has lowered capacity to bind and redox-regulate exogenously added Cu, and (3) responds to treatment with fatty-acid-free albumin by diminished ascorbate oxidizing activity." | ( Borisenko, GG; Fabisiak, JP; Gandley, R; Hubel, CA; Kagan, VE; McLaughlin, MK; Ness, RB; Roberts, JM; Tyurin, VA, 2001) |
| "Current treatment of preeclampsia no longer mandates delivery for proteinuria of >5 g per 24 hours." | ( Dotson, T; Fontenot, MT; Jaekle, RK; Lewis, DF; Newman, MG; Robichaux, AG; Stedman, CM, 2003) |
| "Fifty five women with preeclampsia, eclampsia, and HELLP syndrome administered GTN infusion for the management of hypertension were studied." | ( Cetin, A; Cetin, M; Duran, B; Guvenal, T; Imir, AG; Yurtcu, N, 2004) |
| "In treated women, the relative risk for preeclampsia was 0." | ( Abbate, R; Fatini, C; Gensini, F; Gensini, GF; Marchionni, M; Mello, G; Parretti, E; Riviello, C; Scarselli, GF, 2005) |
| "Seven patients had preeclampsia, 3 had preterm labor treated with aggressive tocolysis, and 5 had underlying cardiac and/or pulmonary disease." | ( Carlson, RJ; Folk, JJ; Lipari, CW; Navone, AJ; Nosovitch, JT; Silverman, RK, 2005) |
| "The increased risk of preeclampsia and phototherapy in the glyburide group warrant further study." | ( Ching, JY; Ferrara, A; Field, DR; Jacobson, GF; Kirby, RS; Ramos, GA, 2005) |
| "Maternal preeclampsia, the presence of labor, maternal treatment with MgSO4, Apgar scores, birth weight, gestational age and respiratory distress syndrome were significantly associated with ENH by univariate analysis." | ( Garrison, RD; Hudak, ML; Sharma, R; Teng, RJ; Wu, TJ, 2006) |
| "Consenting women with suspected mild preeclampsia were randomly assigned to 12 hours or 24 hours of MgSO4 postpartum therapy." | ( Ehrenberg, HM; Mercer, BM, 2006) |
| "Hypertension that complicates preeclampsia in pregnancy is a disorder that requires special consideration in both prevention and pharmacologic treatment." | ( Frishman, WH; Schlocker, SJ; Tejani, N; Veresh, M, 2006) |
| "Preventive treatment of preeclampsia consists essentially of low dose aspirin." | ( Tsasaris, V; Winer, N, 2008) |
| "VEGF attenuates L-NAME-induced preeclampsia-like manifestations in rats, suggesting the important role of VEGF in preeclampsia and providing a potential strategy for the prevention and treatment of preeclampsia." | ( Chen, D; Dong, M; Huang, H; Wang, H, 2008) |
| "The mild preeclampsia group was treated with alpha-methyldopa, while the severe preeclampsia group was treated with a combination of alpha-methyldopa and nifedipine." | ( Gungor, T; Kanat-Pektas, M; Mollamahmutoglu, L; Sucak, A, 2010) |
| "Sixty-six preeclampsia-like pregnant mice, induced by PS/PC microvesicle administration, were randomly divided into six groups." | ( Hu, YL; Shen, Y; Wang, JM; Zhang, Y, 2010) |
| "Sixty-six preeclampsia-like pregnant mice, induced by phosphatidyleserine/phosphatidylcholine (PS/PC) microvesicle administration, were randomly divided into six groups as follows: control group (group C), preeclampsia model group (group PE), group treated with heparin (group H), group treated with aspirin (group A), group treated with low-dose danshensu (group LD), and group treated with high-dose danshensu (group HD)." | ( Hu, Y; Shen, Y; Zhang, Y, 2011) |
| "The pathogenesis of preeclampsia, a serious pregnancy disorder, is still elusive and its treatment empirical." | ( Caniggia, I; Ietta, F; Many, A; Post, M; Racano, A; Rolfo, A; Tagliaferro, A; Tal, R; Wang, J, 2010) |
| "Whether the treatments of preeclampsia were effective on ET-1 induced contraction and could reverse placental ischemia is the question addressed in this study." | ( Barbero-Camps, E; Dechanet, C; Dechaud, H; Fort, A; Richard, S; Virsolvy, A, 2011) |
| "With treatment of preeclampsia being largely unchanged in decades, there is an urgent need for novel therapies particularly those directed at the underlying causes that may allow for extremely preterm delivery, and its myriad consequences, to be avoided." | ( Everett, TR; Lees, CC; Wilkinson, IB, 2012) |
| "The etiology of preeclampsia (PE) is unknown and the only treatment is removal of the fetus and placenta." | ( Bazavilvaso-Rodríguez, MA; Campos-León, S; Galvan-Duarte, RE; Hernández-Valencia, M; Lemus-Rocha, SR; Santillan-Morelos, JG; Saucedo, R; Zarate, A, 2011) |
| "In 5 women with very preterm preeclampsia and elevated circulating sFlt-1 levels, we next demonstrate that a single dextran sulfate cellulose apheresis treatment reduces circulating sFlt-1 levels in a dose-dependent fashion." | ( Benzing, T; Bossung, V; Cornely, OA; Hagmann, H; Hemphill, L; Jank, A; Karumanchi, SA; Khedkar, S; Kisner, T; Kreyssig, C; Kribs, A; Lindner, TH; Mallmann, P; Noack, S; Rigby, AC; Schaarschmidt, W; Stepan, H; Thadhani, R, 2011) |
| "The hallmark of preeclampsia is similar to the toxicities related to antiangiogenesis therapy." | ( Haruta, S; Kobayashi, H; Nagai, A; Naruse, K; Noguchi, T; Sado, T; Tanase, Y; Tsunemi, T; Yoshida, S, 2012) |
| "We discuss the similarity between preeclampsia and VEGF-targeted therapy-induced hypertension." | ( Haruta, S; Kobayashi, H; Nagai, A; Naruse, K; Noguchi, T; Sado, T; Tanase, Y; Tsunemi, T; Yoshida, S, 2012) |
| "Women treated for preeclampsia also have an increased risk for cardiovascular and renal disease." | ( Eiland, E; Faulkner, M; Nzerue, C, 2012) |
| "Several potential biomarkers for preeclampsia have been identified, creating new opportunities for the development of strategies to diagnose, prevent, and treat this disorder." | ( Brkić, J; Fu, G; Ji, L; Liu, M; Peng, C; Wang, YL, 2013) |
| "Women with preeclampsia (before treatment, n=20) and their normotensive counterparts (n=20) did not differ with respect to baseline characteristics, except for earlier gestational age at delivery (36 3/7 [24 4/7-40 2/7] compared with 39 2/7 [32 0/7-41 0/7]; P<." | ( Belfort, MA; Griffioen, AC; Haeri, S; Panerai, RB; van Veen, TR; Zeeman, GG, 2013) |
| "Relative risk of preeclampsia will be the primary measure of treatment effect." | ( Blanchet, C; Boivin, C; Bujold, E; Dodin, S; Lemieux, S; Mogollon, JA; Philippe, K; Turcotte, S, 2013) |
| "Hyponatremia in the setting of preeclampsia is an indicator of severity, and requires the understanding of the etiologic mechanisms to initiate an appropriate treatment." | ( Bodenmann Gobin, P; Ducry, J; Gobin, N; Portmann, L; Vial, Y; Vogt, B, 2014) |
| "Cases were women with preeclampsia treated between January 2006 and June 2007 in the University Hospital of Larissa." | ( Arampatzis, S; Bouchlariotou, S; Eleftheriadis, T; Giannopoulou, M; Liakopoulos, V; Mertens, PR; Messinis, IE; Stefanidis, I; Zintzaras, E, 2014) |
| "Early diagnosis and treatment of preeclampsia are essential for prevention of seizure development and fetus maturation." | ( Dai, L; Gao, L; Gong, Y; Hu, H; Jia, J; Song, C; Wang, T; Wang, Y; Xiong, W; Zhang, L; Zhou, R, 2014) |
| "After modeling, the blood pressure of preeclampsia group was significantly higher than those of control and treatment groups [(143." | ( Jin, Y; Sun, C; Zhang, W, 2015) |
| "22 pregnant women with preeclampsia and 68 normotensive controls were recruited and circulating IL-6 levels in these women were measured before MgSO4 and nifedipine treatment and after delivery." | ( Chamley, LW; Chen, Q; Guo, F; Stone, PR; Xiao, JP; Yin, YX; Zhao, M, 2015) |
| "Circulating levels of IL-6 in preeclampsia were reduced significantly following administration of MgSO4." | ( Chamley, LW; Chen, Q; Guo, F; Stone, PR; Xiao, JP; Yin, YX; Zhao, M, 2015) |
| "We also treated 4 patients with preterm preeclampsia presenting at <30 weeks of gestation with daily pravastatin." | ( Binder, NK; Brownfoot, FC; Cannon, P; Hannan, NJ; Hastie, R; Kaitu'u-Lino, TJ; Onda, K; Tong, S; Walker, SP, 2015) |
| "Totally 704 preeclampsia patients were randomly assigned to the treatment group and the control group, 352 cases in each group." | ( Li, M; Qiu, SQ; Yao, J; Zhang, M; Zheng, XY; Zhu, JM; Zhu, ZX, 2015) |
| "Based on it, a novel rat model of preeclampsia was established by the intraperitoneal administration of cadmium chloride (CdCl2) (0." | ( Chen, Y; Cheng, X; Huang, Y; Jiao, J; Li, Y; Wang, F; Wang, X; Wu, J; Xu, Z; Yan, Y; Ye, D; Zhang, K; Zhang, Q, 2016) |
| "Women at an increased risk of preeclampsia should be offered antiplatelet therapy, regardless of whether they are first seen before or after 16 weeks' gestation." | ( Askie, L; Duley, L; Hunter, K; Meher, S, 2017) |
| "Upon establishing the diagnosis of preeclampsia, aggressive therapy with corticosteroids, antihypertensive medication, and seizure prophylaxis was initiated." | ( Borovac, JA; Bozic, J; Hrboka, V; Kolic, K; Ticinovic Kurir, T; Zaja, N, 2017) |
| "In patients with severe preeclampsia and fetal compromise, fetal acid-base status is independent of the use of bolus ephedrine versus phenylephrine to treat spinal hypotension." | ( Adams, SC; Arcache, MJ; Dyer, RA; Emmanuel, A; Higgins, N; James, MF; Joolay, Y; Lombard, CJ; Reed, AR; Schulein, S; van Dyk, D; Vorster, A; Wong, CA, 2018) |
| "New criteria to diagnose preeclampsia, judicious reliance on measurement of ADAMTS13 to make management decisions in suspected thrombotic thrombocytopenic purpura, new evidence supporting the efficacy and safety of anticomplement therapy for atypical hemolytic uremic syndrome during pregnancy, and implications of thrombotic microangiopathies for subsequent pregnancies are evolving rapidly." | ( Cines, DB; Levine, LD, 2017) |
| "Based on this finding, a rat model of preeclampsia was established by intraperitoneally administrating low-dose cadmium on gestational days 9-12." | ( Chen, Y; Huang, Y; Jiang, W; Wang, F; Wu, J; Xu, H; Yan, Y; Ye, D; Yu, D; Zhang, K; Zhang, Q; Zhao, Y, 2018) |
| "In pregnancies at high risk of preeclampsia administration of aspirin reduces the length of stay in the neonatal intensive care unit by about 70%." | ( de Alvarado, M; de Paco Matallana, C; Jani, JC; Machuca, M; Mastrodima, S; Molina, FS; Nicolaides, KH; Papaioannou, G; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Shearing, S; Syngelaki, A; Tan, MY; Wright, D, 2018) |
| "Inadequately treated, preeclampsia and eclampsia (PE/E) may rapidly lead to severe complications in both mothers and neonates, and are estimated to cause 60,000 global maternal deaths annually." | ( Christmas, A; Ghosh, R; Gore, A; Mahapatra, T; Morgan, MC; Raney, JH; Spindler, H; Sterling, M; Walker, DM, 2019) |
| "Pregnancy outcomes (preeclampsia, preterm delivery, and fetal growth restriction) and neonatal outcomes (gestational age at delivery and birth weight) were compared between HCQ treatment and nontreatment groups." | ( Cha, HS; Chae, J; Choi, SJ; Kim, YM; Oh, S; Roh, CR; Seo, MR, 2019) |
| "A retrospective study of patients with preeclampsia or HELLP syndrome treated at the University of Mississippi Medical Center from January 2000 through December 2010." | ( Bofill, JA; Jayaram, A; Kassahun-Yimer, W; Lee-Plenty, N; Martin, JN; Novotny, S; Wallace, K, 2020) |
| "We employed a preeclampsia animal model induced by ultra-low-dose endotoxin infusion and monitored angiogenic factors, inflammatory response and oxidative stress changes after quercetin treatment." | ( Li, Q; Meng, Y; Si, Y; Yang, W; Yin, L; Zhang, C, 2020) |
| "Then, we compared the preeclampsia and other pregnancy outcomes between HCQ treatment and nontreatment groups." | ( Liu, Y; Wei, Y; Yang, H; Zhang, Y, 2021) |
| "To assess the association of preeclampsia with serum estradiol (E2) and progesterone (P4) levels on the day of human chorionic gonadotropin (hCG) administration during controlled ovarian hyperstimulation (COH) for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI)." | ( Chen, YC; Lai, YJ; Lan, KC; Su, YT; Tsai, NC, 2020) |
| "Eleven women with OAPS that developed preeclampsia (PE) and/or intrauterine growth restriction (IUGR) associated with uteroplacental vascular dysfunction despite treatment with LMWH + LDA participated in this study after given informed written consent." | ( Contento, G; Girardi, G; Jurisic, A; Jurisic, Z; Lefkou, E; Pombo, J; Varoudi, K, 2020) |
| "Simulation of ADMA-like preeclampsia in Wistar rats was performed by the administration of a non-selective NOS blocker L-NAME from the 14th to 20th day of pregnancy." | ( Avdeeva, E; Avdeeva, N; Beskhmelnitsyna, E; Bushueva, O; Denisyuk, T; Golubev, I; Gudyrev, O; Gureev, V; Korokin, M; Korokina, L; Lazareva, G; Peresypkina, A; Pobeda, A; Pokrovskaia, T; Pokrovskii, M; Soldatov, V; Zatolokina, M, 2020) |
| "In addition, the incidence of preeclampsia (PE) is decreased in patients with recurrent spontaneous abortion (RSA) and repeated implantation failure (RIF) treated with CsA during the first trimester." | ( Huang, W; Huang, Y; Li, Q; Lu, W; Luo, S; Ma, Y; Wei, Y; Xie, B; Zhang, Y, 2020) |
| "BACKGROUND Preeclampsia (PE) is a serious complication of pregnancy with no effective therapy." | ( Peng, J; Wang, X; Xiang, L; Yang, X; Zhong, M; Zhu, Y, 2020) |
| "We propose a novel therapy of preeclampsia that is based on immunoneutralization of the marinobufagenin by monoclonal antibodies, which is capable of impairing marinobufagenin-Na/K-ATPase interactions." | ( Adair, CD; Agalakova, NI; Bagrov, AY; Kolodkin, NI; Trashkov, AP, 2021) |
| "Compared with the preeclampsia group, the Garcia test score of ginsenoside Rg2-treated rats was significantly increased." | ( Cai, L; Fu, W; Hu, F; Liu, F; Sui, D; Wang, T; Yu, X; Zhong, W, 2021) |
| "Patients with preeclampsia receiving preoperative magnesium therapy need a greater intraoperative dose of oxytocin to achieve satisfactory contraction of the uterus after fetal delivery, as compared to normotensives." | ( Garg, D; Luthra, A; Malhotra, RK; Mohan, A; Singh, Y; Tyagi, A, 2022) |
| "A total of 100 preeclampsia patients were administered with nicardipine hydrochloride and divided into the low-concentration (LC) and high-concentration (HC) groups." | ( Kong, B; Li, Y; Lu, Q; Ye, F, 2022) |
| "Endotoxin-induced preeclampsia rats treated with ropivacaine via intraspinal administration." | ( Huang, S; Lu, Y; Sun, S; Tian, F, 2022) |
| "Seventy-five parturients with severe preeclampsia scheduled for cesarean delivery under combined spinal-epidural anesthesia were enrolled and randomly allocated to receive a single bolus of phenylephrine at five different doses (40, 50, 60, 70, and 80 μg), whereas 75 parturients with normotension were randomized to receive a single bolus of phenylephrine at five different doses (70, 80, 90, 100, and 110 μg) for the treatment of the first episode of hypotension." | ( Chen, XZ; Hu, LJ; Mei, Z; Qian, XW; Shen, YP; Sheng, ZM; Sun, HT, 2022) |
| "Reportedly, aspirin prevents preeclampsia, specifically early-onset preeclampsia, although findings in decidual arteries in women treated with aspirin therapy remain unclear." | ( Gi, T; Katsuragi, S; Kodama, Y; Maekawa, K; Sameshima, H; Sato, Y; Tomimori-Gi, K; Yamada, N; Yamashita, A, 2022) |
| "To explore the ATF2 expression of preeclampsia patients and investigate whether the level of ATF2 expression impacted the low-dose aspirin treatment of preeclampsia patients." | ( Guo, L; Hu, R; Liu, R; Xiao, S; Zhang, M, 2023) |